<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Primary drugs in pediatric resuscitation</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Primary drugs in pediatric resuscitation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Primary drugs in pediatric resuscitation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark E Ralston, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Torrey, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James F Wiley, II, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 09, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The primary drugs used for pediatric resuscitation are reviewed here.</p><p>Pediatric basic life support (BLS), pediatric advanced life support (PALS), and the use of <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">naloxone</a> in children with opioid intoxication are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6384.html" rel="external">"Pediatric basic life support (BLS) for health care providers"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6392.html" rel="external">"Pediatric advanced life support (PALS)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6504.html" rel="external">"Opioid intoxication in children and adolescents", section on 'Naloxone'</a>.)</p><p></p><p class="headingAnchor" id="H5952713"><span class="h1">DRUG THERAPY BY CLINICAL CONDITION</span><span class="headingEndMark"> — </span>In children undergoing pediatric advanced life support (PALS), medications are of secondary importance to the prompt treatment of hypoxemia and respiratory failure, and initiation of high-quality basic life support (BLS), including cardiopulmonary resuscitation (CPR) (see  <a class="medical medical_review" href="/z/d/html/6384.html" rel="external">"Pediatric basic life support (BLS) for health care providers", section on 'Basic life support approach'</a> and  <a class="medical medical_review" href="/z/d/html/6392.html" rel="external">"Pediatric advanced life support (PALS)"</a>): </p><p class="bulletIndent2"><span class="glyph">•</span>CPR – In patients with cardiac arrest or bradycardia with poor perfusion </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Defibrillation – In patients with pulseless ventricular arrhythmias (ventricular fibrillation [VF], pulseless ventricular tachycardia [pVT], or torsades de pointes [TdP]) </p><p></p><p>The primary drugs used in PALS and pediatric resuscitation according to clinical presentation are as follows  (<a class="graphic graphic_table graphicRef70539" href="/z/d/graphic/70539.html" rel="external">table 1</a>) [<a href="#rid1">1</a>] (see  <a class="medical medical_review" href="/z/d/html/6392.html" rel="external">"Pediatric advanced life support (PALS)"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypoxemia</strong> – Oxygen.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypoglycemia</strong> – Dextrose (glucose).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac arrest with nonshockable rhythm (asystole or pulseless electrical activity [PEA])</strong> – Oxygen, <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> as adjuncts to high-quality CPR  (<a class="graphic graphic_algorithm graphicRef129942" href="/z/d/graphic/129942.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac arrest with shockable rhythm (VF, pVT, or TdP)</strong> – Oxygen, <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a>, and, as adjuncts to high-quality CPR and defibrillation:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For VF and pVT, <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">lidocaine</a> or <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">amiodarone</a>  (<a class="graphic graphic_algorithm graphicRef129942" href="/z/d/graphic/129942.html" rel="external">algorithm 1</a>)</p><p class="bulletIndent3"><span class="glyph">-</span>For TdP, <a class="drug drug_pediatric" data-topicid="12982" href="/z/d/drug information/12982.html" rel="external">magnesium sulfate</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac arrest associated with hyperkalemia or sodium channel blocker (eg, tricyclic antidepressant) overdose</strong> – In addition to the medications above, <a class="drug drug_pediatric" data-topicid="12795" href="/z/d/drug information/12795.html" rel="external">sodium bicarbonate</a>; severe hyperkalemia can also cause asystole or PEA. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Narrow-complex tachycardia (supraventricular tachycardia [SVT])</strong> – Oxygen, <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a>, and, preferably in consultation with a pediatric cardiologist, <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">amiodarone</a> or <a class="drug drug_pediatric" data-topicid="12732" href="/z/d/drug information/12732.html" rel="external">procainamide</a> as adjuncts to indicated vagal maneuvers and synchronized cardioversion  (<a class="graphic graphic_algorithm graphicRef129940" href="/z/d/graphic/129940.html" rel="external">algorithm 2</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Wide-complex tachycardia (ventricular tachycardia [VT] or aberrant SVT)</strong> – Oxygen, and, as adjuncts to indicated synchronized cardioversion  (<a class="graphic graphic_algorithm graphicRef129940" href="/z/d/graphic/129940.html" rel="external">algorithm 2</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For VT, and in consultation with a pediatric cardiologist, <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">lidocaine</a> or <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">amiodarone</a>.</p><p class="bulletIndent3"><span class="glyph">-</span>For aberrant SVT, <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a>; if adenosine is unsuccessful and, in consultation with a pediatric cardiologist, <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">amiodarone</a> or <a class="drug drug_pediatric" data-topicid="12732" href="/z/d/drug information/12732.html" rel="external">procainamide</a>. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bradycardia with poor perfusion</strong> – Oxygen, <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a>, <a class="drug drug_pediatric" data-topicid="12875" href="/z/d/drug information/12875.html" rel="external">atropine</a> as adjuncts to high-quality CPR (for heart rate &lt;60 per minute)  (<a class="graphic graphic_algorithm graphicRef129941" href="/z/d/graphic/129941.html" rel="external">algorithm 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fluid-refractory</strong> <strong>septic shock </strong>–<strong> </strong>First-line agents: <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> or norepinephrine; indications and dosing are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/85767.html" rel="external">"Septic shock in children in resource-abundant settings: Rapid recognition and initial resuscitation (first hour)", section on 'Patients with fluid-refractory shock'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiogenic shock</strong> – Vasoactive medication options include continuous infusions of <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a>, <a class="drug drug_pediatric" data-topicid="13248" href="/z/d/drug information/13248.html" rel="external">dopamine</a>, <a class="drug drug_pediatric" data-topicid="13243" href="/z/d/drug information/13243.html" rel="external">dobutamine</a>, or <a class="drug drug_pediatric" data-topicid="12613" href="/z/d/drug information/12613.html" rel="external">milrinone</a>. (See  <a class="medical medical_review" href="/z/d/html/6397.html" rel="external">"Shock in children in resource-abundant settings: Initial management", section on 'Vasoactive agents'</a> and  <a class="medical medical_review" href="/z/d/html/5761.html" rel="external">"Treatment and prognosis of myocarditis in children", section on 'Decompensated heart failure/cardiogenic shock'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypocalcemia, hypermagnesemia, hyperkalemia or calcium channel blocker overdose</strong> – For patients with significant electrocardiogram (ECG) findings, <a class="drug drug_pediatric" data-topicid="12651" href="/z/d/drug information/12651.html" rel="external">calcium chloride</a> or <a class="drug drug_pediatric" data-topicid="12956" href="/z/d/drug information/12956.html" rel="external">calcium gluconate</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypomagnesemia or torsades de pointes</strong> <strong>(TdP)</strong> – <a class="drug drug_pediatric" data-topicid="12982" href="/z/d/drug information/12982.html" rel="external">Magnesium sulfate</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Opioid intoxication</strong> – The use of <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">naloxone</a> for children with suspected opioid intoxication and clinical findings of coma, depressed respirations, and/or miosis is discussed in the table  (<a class="graphic graphic_table graphicRef69375" href="/z/d/graphic/69375.html" rel="external">table 2</a>) and provided separately. (See  <a class="medical medical_review" href="/z/d/html/6504.html" rel="external">"Opioid intoxication in children and adolescents", section on 'Naloxone'</a>.)</p><p></p><p class="headingAnchor" id="H4897046"><span class="h1">SUBSTRATE DELIVERY</span></p><p class="headingAnchor" id="H2"><span class="h2">Oxygen</span><span class="headingEndMark"> — </span>The fundamental goal of pediatric basic and advanced life support (BLS and PALS) is to support cerebral, myocardial, and systemic oxygenation before irreversible injury occurs. Because respiratory compromise is the leading cause of cardiac arrests in children, 100 percent oxygen should be administered to any child who is suspected of being hypoxemic using an appropriate delivery device. The potential negative effects of high concentrations of oxygen are <strong>not</strong> a consideration in the setting of cardiac arrest. (See  <a class="medical medical_review" href="/z/d/html/6394.html" rel="external">"Continuous oxygen delivery systems for the acute care of infants, children, and adults"</a> and  <a class="medical medical_review" href="/z/d/html/1622.html" rel="external">"Adverse effects of supplemental oxygen"</a>.)</p><p>However, in perfusing patients and those who were in cardiac arrest but with return of spontaneous circulation (ROSC), oxygen therapy should be titrated to maintain PaO<sub>2 </sub>between 60 and 300 mmHg or pulse oximetry of 94 to 99 percent to avoid oxygen toxicity [<a href="#rid2">2-6</a>]. (See  <a class="medical medical_review" href="/z/d/html/6392.html" rel="external">"Pediatric advanced life support (PALS)", section on 'Avoid low and high arterial oxygen'</a> and  <a class="medical medical_review" href="/z/d/html/140197.html" rel="external">"Initial post-cardiac arrest care in children", section on 'Oxygenation (pulse oximetry target)'</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Dextrose (glucose)</span><span class="headingEndMark"> — </span>Hypoglycemia may accompany trauma, respiratory failure, shock, sepsis, and many other illnesses that result in cardiac arrest. Small infants are particularly prone to developing hypoglycemia because of inadequate glycogen stores. In addition, acute illness may have caused decreased caloric intake or excessive losses (eg, from diarrhea and vomiting).</p><p>A rapid bedside glucose test should be performed in all pediatric patients who are clinically unstable because the clinical signs of hypoglycemia and hypoxemia are similar (eg, altered mental status, poor perfusion, tachycardia, and hypotension). (See  <a class="medical medical_review" href="/z/d/html/5805.html" rel="external">"Approach to hypoglycemia in infants and children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanisms</strong> – Glucose is the primary metabolic substrate for the neonatal myocardium, and hypoglycemia may contribute to myocardial dysfunction [<a href="#rid7">7</a>]. Glucose is also a significant energy source in older infants and children during periods of ischemia [<a href="#rid7">7</a>]. Whether glucose administration improves cardiac function or survival in hypoglycemic children with cardiac arrest is not known [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and contraindications </strong>– During pediatric resuscitation, patients with a low bedside glucose (&lt;60 mg/dL [3.3 mmol/L]) warrant treatment, but routine administration of glucose without evaluation of the serum glucose is <strong>not</strong> recommended [<a href="#rid7">7</a>]. Empiric treatment with glucose may be appropriate if bedside glucose determination is <strong>not</strong> available and the infant or child has symptoms of severe hypoglycemia or is at risk for developing hypoglycemia. Symptomatic patients with a bedside glucose between 60 and 70 mg/dL (3.89 mmol/L) may also warrant treatment, especially if they have a condition such as diabetes mellitus, which has led to habituation to a higher-than-normal baseline blood glucose. (See  <a class="medical medical_review" href="/z/d/html/5805.html" rel="external">"Approach to hypoglycemia in infants and children"</a>.)</p><p></p><p class="bulletIndent1">The routine administration of glucose during pediatric resuscitation is <strong>not</strong> recommended because of the absence of data demonstrating benefit and the potential harm of hyperglycemia. Large volumes of dextrose-containing fluids should not be given to normoglycemic children during resuscitation because they can cause hyperglycemia, which can induce osmotic diuresis, produce or aggravate hypokalemia, or worsen ischemic brain injury [<a href="#rid7">7-10</a>]. Evidence for the harm of empiric glucose administration is lacking; there is evidence of poor neurologic outcomes for neonates with dysglycemia [<a href="#rid11">11,12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and administration</strong> – The dose of intravenous (IV) dextrose (glucose) for symptomatic hypoglycemia is 0.5 to 1 g/kg per American Heart Association (AHA) recommendations [<a href="#rid7">7</a>]. However, other experts have suggested a lower dose of 0.2 to 0.25 g/kg to avoid unintentional osmotic diuresis. (See  <a class="medical medical_review" href="/z/d/html/5805.html" rel="external">"Approach to hypoglycemia in infants and children", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1">It should be administered via intravenous (IV) or intraosseous (IO) infusion. The maximum concentration of dextrose that can be administered through a peripheral vein is 25 percent dextrose in water (D25W); higher concentrations cause sclerosis of peripheral veins. Thus, 50 percent solutions of dextrose in water (D50W) must be diluted 1:1 with sterile water before peripheral administration in children. However, in infants and children younger than five years of age, 10 percent dextrose in water (D10W) is typically used.</p><p></p><p class="bulletIndent1">The volume of solution necessary to achieve the desired dose varies depending upon the dextrose concentration of the solution. Each of the following alternatives provides 0.5 to 1 g/kg of dextrose [<a href="#rid7">7</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>D25W 2 to 4 mL/kg</p><p class="bulletIndent2"><span class="glyph">•</span>D10W 5 to 10 mL/kg </p><p></p><p class="bulletIndent1">Children with hypoglycemia due to a sulfonylurea overdose may especially warrant this higher initial dose of dextrose. (See  <a class="medical medical_review" href="/z/d/html/308.html" rel="external">"Sulfonylurea agent poisoning", section on 'Hypoglycemia'</a>.)</p><p></p><p class="bulletIndent1">After the initial dextrose infusion, the unconscious child should receive additional <a class="drug drug_pediatric" data-topicid="13222" href="/z/d/drug information/13222.html" rel="external">IV dextrose</a> at an infusion rate that will maintain glucose levels (5 to 6 mg/kg per minute in infants and 2 to 3 mg/kg per minute in children) and undergo frequent measurement of blood glucose. (See  <a class="medical medical_review" href="/z/d/html/5805.html" rel="external">"Approach to hypoglycemia in infants and children", section on 'Treatment'</a>.)</p><p></p><p class="headingAnchor" id="H4897086"><span class="h1">CARDIAC ARREST AND BRADYCARDIA WITH POOR PERFUSION</span></p><p class="headingAnchor" id="H6"><span class="h2">Epinephrine</span><span class="headingEndMark"> — </span>Administration of <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> is the intervention most likely to be of benefit in pediatric cardiac arrest when basic life support (BLS) and fluid resuscitation do not restore effective circulation  (<a class="graphic graphic_algorithm graphicRef129942" href="/z/d/graphic/129942.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef70539" href="/z/d/graphic/70539.html" rel="external">table 1</a>) [<a href="#rid13">13,14</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanisms</strong> – <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">Epinephrine</a> is a catecholamine with actions that include both alpha- and beta-adrenergic stimulation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Alpha-adrenergic stimulation </strong>– The alpha-mediated peripheral arterial vasoconstriction is the beneficial action of <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> in cardiac arrest. Peripheral arterial vasoconstriction elevates systemic vascular resistance (SVR), thereby increasing the aortic-right atrial pressure gradient during the decompression phase of cardiopulmonary resuscitation (CPR). This gradient, also called the coronary perfusion pressure, correlates directly with myocardial blood flow in animal models and is a good predictor of return of spontaneous circulation (ROSC) in animals and humans [<a href="#rid15">15-17</a>].</p><p></p><p class="bulletIndent2">In addition, increased SVR raises the arterial pressure during the compression phase of CPR, thereby raising the cerebral perfusion pressure [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent2">Thus, the administration of <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> increases blood flow to both the heart and the brain. Additional alpha-adrenergic vasoconstrictor effects of epinephrine include reduced blood flow to the splanchnic, renal, mucosal, and dermal vascular beds [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Beta-adrenergic stimulation </strong>– Beta-adrenergic stimulation increases myocardial contractility and heart rate and relaxes smooth muscle in the coronary arteries, cerebral arteries, skeletal muscle vascular beds, and bronchi [<a href="#rid7">7,19</a>]. Other effects of <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> include stimulation of spontaneous cardiac contraction in asystole and enhanced ability to terminate ventricular fibrillation (VF) by electrical defibrillation [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and contraindications</strong> – <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">Epinephrine</a> is indicated for the treatment of cardiac arrest (ie, for both nonshockable and shockable rhythms), bradycardia with poor perfusion, and, as discussed separately, fluid-refractory hypotensive shock [<a href="#rid2">2,7,21-23</a>]. (See  <a class="medical medical_review" href="/z/d/html/85767.html" rel="external">"Septic shock in children in resource-abundant settings: Rapid recognition and initial resuscitation (first hour)", section on 'Patients with fluid-refractory shock'</a>.)</p><p></p><p class="bulletIndent1">Asystole and bradyarrhythmias are the most common rhythms in pediatric cardiac arrest [<a href="#rid7">7</a>]. The administration of <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> to children with these rhythms may generate a perfusing pressure [<a href="#rid24">24</a>]. In addition, the use of epinephrine in children with VF, an uncommon rhythm in pediatric cardiac arrest, may render the rhythm more susceptible to electrical defibrillation [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1">Contraindications to the use of <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> are rare in children and consist of:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypersensitivity to </strong><a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a><strong> or one of its components</strong> – A true allergy to epinephrine is rare, and during a cardiac arrest, the benefit of epinephrine administration should be weighed against the potential harm. <a class="drug drug_pediatric" data-topicid="12876" href="/z/d/drug information/12876.html" rel="external">Vasopressin</a> may be an alternative, as discussed below. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Narrow angle glaucoma</strong> – The risk of worsening narrow angle glaucoma will rarely outweigh the benefit for children in cardiac arrest with this uncommon condition. The clinician should weigh the harm of worsening narrow angle glaucoma with the benefit of <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> administration in children with cardiac arrest in those rare instances in which a patient is known to carry this diagnosis. For children with bradycardia with poor perfusion, <a class="drug drug_pediatric" data-topicid="12875" href="/z/d/drug information/12875.html" rel="external">atropine</a> and, if necessary, transthoracic or intravenous (IV) pacing may be attempted rather than giving epinephrine.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and administration</strong> – The dose of <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> varies depending on the route of administration. Intravenous (IV) or intraosseous (IO) routes are preferred, although it can be given by the endotracheal (ET) route [<a href="#rid1">1,2,25-27</a>]. Epinephrine should be administered through a secure intravascular line because infiltration into the tissues may cause local ischemia, which may lead to tissue injury and ulceration [<a href="#rid24">24</a>]. Epinephrine is inactivated by alkaline solutions and should not be added to solutions containing <a class="drug drug_pediatric" data-topicid="12795" href="/z/d/drug information/12795.html" rel="external">sodium bicarbonate</a>. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bolus dose </strong>– The IV or IO bolus dose of <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> is 0.01 mg/kg given as 0.1 mL/kg of the 0.1 mg/mL concentration given within five minutes from the start of chest compressions [<a href="#rid2">2,28-32</a>]. Repeated doses may be given every three to five minutes until ROSC is achieved [<a href="#rid1">1,2,33,34</a>]. </p><p></p><p class="bulletIndent2">To help prevent medication errors, ratio expressions have been removed from <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> labels in the United States [<a href="#rid35">35</a>]. Ampules, vials, and syringes of epinephrine with ratio expressions may, however, remain in inventory until replaced by products with revised labeling. <strong>Therefore, the 0.1 mg/mL concentration of epinephrine may be labeled as 1:10,000 and the 1 mg/mL concentration may be labeled as 1:1000</strong>.</p><p></p><p class="bulletIndent2">The efficacy of bolus doses of <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> in children with cardiac arrest differs by setting: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>In-hospital cardiac arrest (IHCA)</strong> – In a single-center retrospective cohort study of pediatric IHCA in which patients received at least two doses of <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a>, a dosing interval &lt;2 minutes was associated with increased survival with favorable neurobehavioral outcome compared with a dosing interval &gt;2 minutes (adjusted odds ratio [aOR] 2.56, 95% CI 1.07-6.14; p = 0.036) with 66 percent of the association mediated by CPR duration [<a href="#rid36">36</a>]. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Out-of-hospital cardiac arrest</strong> <strong>(OHCA) </strong>– In a population-based observational study of pediatric OHCA, administration of <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> was associated with an improved rate of prehospital ROSC compared with no epinephrine (relative risk [RR] 3.17, 95% CI 1.54-6.54), but no significant difference was noted between the two groups in one-month survival or favorable neurological outcome [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent2">High-dose <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> (HDE) is <strong>no longer</strong> recommended for use in pediatric resuscitation [<a href="#rid1">1</a>]. In a controlled trial of children with IHCA who were randomly assigned to receive HDE or standard-dose epinephrine (SDE) after failure of an initial dose of SDE, HDE was associated with a trend towards an increased risk of death (aOR 7.9, 95% CI 0.9-72.5) and no observed increase in ROSC compared with SDE [<a href="#rid38">38</a>]. These findings confirm the lack of benefit for HDE observed in retrospective pediatric studies and suggest a risk of harm [<a href="#rid39">39,40</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Continuous </strong><a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a><strong> infusion</strong> – Continuous infusions of epinephrine are used in children with ROSC after cardiac arrest, bradycardia with poor perfusion unresponsive to oxygen and ventilation after treatment with bolus dose epinephrine  (<a class="graphic graphic_algorithm graphicRef129941" href="/z/d/graphic/129941.html" rel="external">algorithm 3</a>), or hypotensive fluid-refractory shock. </p><p></p><p class="bulletIndent2">The dose is 0.1 to 1 mcg/kg per minute titrated to desired effect  (<a class="graphic graphic_table graphicRef56049" href="/z/d/graphic/56049.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef66791" href="/z/d/graphic/66791.html" rel="external">table 4</a>) [<a href="#rid7">7,19,41</a>]. </p><p></p><p class="bulletIndent2">In infants and children with fluid-refractory hypotensive septic shock, an IV (central or peripheral) or IO infusion of <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> or norepinephrine are first-line agents as discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/85767.html" rel="external">"Septic shock in children in resource-abundant settings: Rapid recognition and initial resuscitation (first hour)", section on 'Patients with fluid-refractory shock'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Endotracheal (ET) </strong>– The recommended dose of <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> when given by the ET route is 0.1 mg/kg given as 0.1 mL/kg of the 1 mg/mL concentration, which can also be repeated every three to five minutes until ROSC is achieved [<a href="#rid1">1,2,33,34</a>]. The ET dosing of epinephrine in neonates is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5015.html" rel="external">"Neonatal resuscitation in the delivery room", section on 'Epinephrine'</a>.)</p><p></p><p class="bulletIndent2">Higher doses of <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> are required for ET administration because peak levels achieved via this route are less than 10 percent of those achieved with IV administration [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent2">Administration of medications by the ET route is discussed below. (See <a class="local">'Endotracheal drug administration'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects </strong>– Despite the recognized benefits of increasing coronary and cerebral perfusion pressures, evidence has shown a negative safety profile of <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> due to its ability to increase myocardial workload, decrease subendocardial perfusion, and induce ventricular arrhythmias [<a href="#rid43">43</a>]. Most of the evidence on the toxicity of epinephrine has been described in hemodynamically intact animals and adults. Whether these results can be applied to the low flow state present during cardiac arrest is not clear [<a href="#rid16">16,41</a>]. Very high doses of epinephrine have been associated with a pattern of myocardial injury called "contraction band necrosis" [<a href="#rid44">44</a>]. Damage to the arterial vascular endothelium also may occur [<a href="#rid45">45</a>]. One study found that adult patients receiving more than 15 mg cumulative-dose epinephrine had an increased mortality rate at 24 hours after arrest compared with patients receiving less than 15 mg [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12876" href="/z/d/drug information/12876.html" rel="external">Vasopressin</a><strong> versus </strong><a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a><strong> </strong>– Vasopressin is not included in the consensus pediatric cardiac arrest algorithm, although it may be used as an alternative to epinephrine in children with a known hypersensitivity to epinephrine or its components. </p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12876" href="/z/d/drug information/12876.html" rel="external">Vasopressin</a> is a nonadrenergic endogenous peptide that induces peripheral, coronary, and renal vasoconstriction via stimulation of Vasopression1 receptors, lacks the adverse effects of <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a>, and has gained much attention as a replacement vasopressor [<a href="#rid47">47</a>]. Another possible advantage of vasopressin is that Vasopressin2 receptor stimulation induces vasodilation and may lessen the end-organ hypoperfusion thought to occur with epinephrine [<a href="#rid48">48</a>]. However, randomized double-blind controlled trial of epinephrine plus vasopressin during treatment of pediatric cardiac arrest did not improve the rate of ROSC compared with epinephrine plus placebo [<a href="#rid49">49</a>]. In addition, a large National Registry of Cardiopulmonary Resuscitation (NRCPR) retrospective observational study found that vasopressin was associated with a lower frequency of ROSC, and a trend toward lower 24-hour and discharge survival [<a href="#rid50">50</a>]. </p><p></p><p class="bulletIndent1">The role of <a class="drug drug_pediatric" data-topicid="12876" href="/z/d/drug information/12876.html" rel="external">vasopressin</a> in children with hypotensive fluid-refractory shock is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/86881.html" rel="external">"Septic shock in children in resource-abundant settings: Ongoing management after resuscitation", section on 'Vasoactive drug therapy'</a>.) </p><p></p><p class="headingAnchor" id="H4897154"><span class="h1">TACHYCARDIAS AND CARDIAC ARREST (SHOCKABLE RHYTHM)</span></p><p class="headingAnchor" id="H4895863"><span class="h2">Adenosine</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">Adenosine</a> is the primary drug of choice for supraventricular tachycardia (SVT) in children  (<a class="graphic graphic_table graphicRef70539" href="/z/d/graphic/70539.html" rel="external">table 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanisms</strong> – <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">Adenosine</a> interacts with Adenosine1 receptors on the surface of cardiac cells; the resulting effects include slowing of the sinus rate and an increase in the atrioventricular (AV) node conduction delay. These actions interrupt the reentrant circuit of tachycardias that require the AV node for reentry, which account for the great majority of cases of SVT in children. While adenosine is effective in terminating SVT associated with AV node reentry, AV reentry tachycardia associated with an accessory pathway, sinus node reentry, and automatic atrial tachycardia, it is <strong>not</strong> effective for atrial flutter, atrial fibrillation, or tachycardias that are <strong>not</strong> caused by reentry at the AV node. (See  <a class="medical medical_review" href="/z/d/html/5782.html" rel="external">"Management of supraventricular tachycardia (SVT) in children", section on 'First-line therapy (adenosine)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indication and contraindications</strong> – <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">Adenosine</a> is the primary drug of choice for the treatment of SVT, in both hemodynamically stable and unstable children  (<a class="graphic graphic_algorithm graphicRef129940" href="/z/d/graphic/129940.html" rel="external">algorithm 2</a> and <a class="graphic graphic_table graphicRef53559" href="/z/d/graphic/53559.html" rel="external">table 5</a> and <a class="graphic graphic_waveform graphicRef70842" href="/z/d/graphic/70842.html" rel="external">waveform 1</a>) [<a href="#rid2">2,51-56</a>]. Vagal maneuvers may be attempted first unless the patient is hemodynamically unstable or it will delay adenosine administration or synchronized cardioversion [<a href="#rid2">2,57,58</a>]. </p><p></p><p class="bulletIndent1">In patients with Wolff-Parkinson-White (WPW) syndrome, <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a> can precipitate atrial fibrillation that can degenerate into ventricular fibrillation (VF). This is an extremely rare event and does <strong>not</strong> imply that adenosine should be avoided in patients with WPW. To the contrary, adenosine is considered the first-line treatment for SVT in patients with WPW. However, clinicians should be aware of this potential adverse effect and have emergency resuscitation equipment immediately available during administration. (See  <a class="medical medical_review" href="/z/d/html/5782.html" rel="external">"Management of supraventricular tachycardia (SVT) in children", section on 'Supraventricular tachycardia refractory to vagal maneuvers'</a> and  <a class="medical medical_review" href="/z/d/html/996.html" rel="external">"Treatment of arrhythmias associated with the Wolff-Parkinson-White syndrome", section on 'Orthodromic AVRT'</a>.) </p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">Adenosine</a> is also contraindicated in patients with pre-existing second- or third-degree heart block or sinus node disease. (See  <a class="medical medical_review" href="/z/d/html/5782.html" rel="external">"Management of supraventricular tachycardia (SVT) in children", section on 'First-line therapy (adenosine)'</a>.)</p><p></p><p class="bulletIndent1">Although <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a> is considered to be the primary drug of choice for conversion of SVT in children, there are some children with frequently recurrent or refractory SVT who are poorly responsive to adenosine. These patients commonly have impaired ventricular function or are recovering from surgery for congenital heart disease [<a href="#rid59">59</a>]. <a class="drug drug_pediatric" data-topicid="12732" href="/z/d/drug information/12732.html" rel="external">Procainamide</a> or <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">amiodarone</a> may be considered for the patient with hemodynamically unstable SVT unresponsive to vagal maneuvers, intravenous (IV) adenosine, and synchronized cardioversion, preferably in consultation with a pediatric cardiologist [<a href="#rid2">2,59,60</a>]. (See <a class="local">'Procainamide'</a> below and <a class="local">'Amiodarone'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and administration</strong> – The usual initial dose of <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a> for SVT is 0.1 mg/kg rapid IV push (maximum first dose 6 mg) followed immediately with a 5 mL <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">saline</a> flush to promote drug entry into the systemic circulation. Dosing is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/5782.html" rel="external">"Management of supraventricular tachycardia (SVT) in children", section on 'First-line therapy (adenosine)'</a>.)</p><p></p><p class="bulletIndent1">Because the elimination half-life of <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a> is 10 seconds, it should be given in an IV line as close to the heart as possible. If adenosine is given too slowly or with an inadequate <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">saline</a> flush, then less of the drug may reach the heart and decrease efficacy. The use of two syringes (one with adenosine and the other with normal saline flush) connected to a T-connector or a stopcock is a useful way of ensuring rapid and effective drug delivery.</p><p></p><p class="bulletIndent1">A systematic review of five case series (232 infants and children) suggests that an <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a> dose of 0.1 mg/kg will successfully reverse SVT in 20 to 65 percent of patients [<a href="#rid61">61</a>]. Subsequent doses may be increased by 0.1 mg/kg to a maximum single dose of 0.3 mg/kg (maximum total single dose 12 mg). In children &gt;50 kg, the initial adult dose of 6 mg should be given with subsequent doses being the maximum single dose of 12 mg. (See  <a class="medical medical_review" href="/z/d/html/5782.html" rel="external">"Management of supraventricular tachycardia (SVT) in children", section on 'First-line therapy (adenosine)'</a>.)</p><p></p><p class="bulletIndent1">The most common side effects reported after <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a> administration are flushing, chest pain, nausea, and headache. Transient sinus bradycardia or heart block may occur, usually lasting between 10 and 40 seconds. Bronchospasm has been reported in patients with asthma who receive adenosine. (See  <a class="medical medical_review" href="/z/d/html/5782.html" rel="external">"Management of supraventricular tachycardia (SVT) in children", section on 'First-line therapy (adenosine)'</a>.)</p><p></p><p class="headingAnchor" id="H4895234"><span class="h2">Procainamide</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="12732" href="/z/d/drug information/12732.html" rel="external">Procainamide</a> is a class IA antiarrhythmic that is an alternative to <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">amiodarone</a> for the treatment of SVT refractory to <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a> or hemodynamically stable ventricular tachycardia (VT)  (<a class="graphic graphic_table graphicRef70539" href="/z/d/graphic/70539.html" rel="external">table 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanisms</strong> – <a class="drug drug_pediatric" data-topicid="12732" href="/z/d/drug information/12732.html" rel="external">Procainamide</a> is a sodium channel blocker that prolongs the refractory period of both the atria and ventricles and slows conduction velocity. Unlike <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a>, procainamide does not block reentry at the AV node and can be safely used in patients with WPW syndrome. (See  <a class="medical medical_review" href="/z/d/html/5782.html" rel="external">"Management of supraventricular tachycardia (SVT) in children", section on 'Supraventricular tachycardia refractory to adenosine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and contraindications</strong> – <a class="drug drug_pediatric" data-topicid="12732" href="/z/d/drug information/12732.html" rel="external">Procainamide</a> is suggested for the treatment of SVT that is unresponsive to <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a> and hemodynamically stable VT [<a href="#rid2">2</a>]. Procainamide may be more effective than <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">amiodarone</a> in patients with refractory supraventricular arrhythmias. As an example, in an observational study of 37 pediatric patients (24 with congenital heart disease), procainamide was significantly more effective than amiodarone in terminating refractory SVT (50 versus 15 percent) without an observed difference in adverse effects [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12732" href="/z/d/drug information/12732.html" rel="external">Procainamide</a> should be <strong>avoided</strong> in patients who have received <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">amiodarone</a>. It is contraindicated for patients with allergy to procainamide or related drugs (eg, procaine penicillin), heart block (eg, complete or second-degree heart block), or torsades de pointes (TdP).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and administration</strong> – Consultation with a pediatric cardiologist is advised. The IV loading dose depends upon patient age:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neonates – 7 to 10 mg/kg [<a href="#rid62">62,63</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Older infants and children – 15 mg/kg (maximum dose, 1 g) [<a href="#rid63">63,64</a>]</p><p></p><p class="bulletIndent1">To avoid transient hypotension caused by rapid administration, give the loading dose slowly over 30 to 60 minutes. During loading, ensure frequent blood pressure measurements and continuous electrocardiogram (ECG) monitoring.</p><p></p><p class="bulletIndent1">For stable patients in normal sinus rhythm who are receiving <a class="drug drug_pediatric" data-topicid="12732" href="/z/d/drug information/12732.html" rel="external">procainamide</a>, stop administration if the QRS interval increases &gt;50 percent from baseline or an arrhythmia develops [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1">After the loading dose, start a continuous IV infusion at 20 mcg/kg per minute and titrate up to a maximum dose of 80 mcg/kg per minute as needed for rhythm control (maximum daily dose, 2 g over 24 hours). Measure plasma levels (<a class="drug drug_pediatric" data-topicid="12732" href="/z/d/drug information/12732.html" rel="external">procainamide</a> and N-acetyl procainamide) four hours after completion of the loading dose [<a href="#rid62">62,63</a>].</p><p></p><p class="bulletIndent1">Adverse effects of <a class="drug drug_pediatric" data-topicid="12732" href="/z/d/drug information/12732.html" rel="external">procainamide</a> include heart block, negative inotropic effects, and prolongation of the QRS and QT intervals (which will predispose to ventricular arrhythmias and TdP) [<a href="#rid63">63,65</a>].</p><p></p><p class="bulletIndent1">Use lower doses in patients with renal impairment to avoid supratherapeutic levels [<a href="#rid62">62,63</a>].</p><p></p><p class="headingAnchor" id="H3700568482"><span class="h2">Amiodarone</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">Amiodarone</a> may be used for the treatment of pulseless ventricular arrhythmias and is also potentially useful for supraventricular and stable ventricular arrhythmias  (<a class="graphic graphic_table graphicRef70539" href="/z/d/graphic/70539.html" rel="external">table 1</a>). Either amiodarone or <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">lidocaine</a> is an appropriate medication for the initial treatment of shock-refractory ventricular arrhythmias in children [<a href="#rid2">2</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanisms</strong> – <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">Amiodarone</a> is a class III antiarrhythmic agent that slows AV node conduction, prolongs the AV node refractory period and QT interval, and slows ventricular conduction (widens the QRS). These actions are mediated through effects on sodium, potassium, and calcium channels as well as blocking alpha- and beta-adrenergic receptors. (See  <a class="medical medical_review" href="/z/d/html/926.html" rel="external">"Amiodarone: Clinical uses", section on 'Pharmacokinetics'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and contraindications</strong> – <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">Amiodarone</a> is effective in treating both ventricular and supraventricular arrhythmias that are resistant to other therapies. </p><p></p><p class="bulletIndent1">In children, <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">amiodarone</a> is suggested for the treatment of pulseless ventricular arrhythmias or hemodynamically stable VT. Based upon the pediatric cardiac arrest algorithm  (<a class="graphic graphic_algorithm graphicRef129942" href="/z/d/graphic/129942.html" rel="external">algorithm 1</a>), amiodarone is <strong>not</strong> preferred over <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">lidocaine</a> for the treatment of shock-refractory VF or pulseless ventricular tachycardia (pVT) [<a href="#rid2">2,66-69</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">Amiodarone</a> is also used for SVT that is refractory to <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a> [<a href="#rid2">2</a>]. However, <a class="drug drug_pediatric" data-topicid="12732" href="/z/d/drug information/12732.html" rel="external">procainamide</a> may be more effective in this situation. (See <a class="local">'Procainamide'</a> above and <a class="local">'Adenosine'</a> above and  <a class="medical medical_review" href="/z/d/html/5782.html" rel="external">"Management of supraventricular tachycardia (SVT) in children", section on 'Supraventricular tachycardia refractory to adenosine'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">Amiodarone</a> should not be administered together with another drug that causes QT prolongation, such as <a class="drug drug_pediatric" data-topicid="12732" href="/z/d/drug information/12732.html" rel="external">procainamide</a>, without expert consultation [<a href="#rid1">1</a>]. It is <strong>contraindicated</strong> in patients with congenital prolonged QT syndrome because it can exacerbate ventricular arrhythmias [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent1">In a small pediatric case series of 40 children who did not respond to standard therapy, 80 percent had successful cessation of critical tachyarrhythmias (eg, atrial or ventricular tachyarrhythmias, junctional ectopic tachycardia) after receiving IV <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">amiodarone</a> [<a href="#rid71">71</a>]. Most of these patients developed these arrhythmias after cardiac surgery.</p><p></p><p class="bulletIndent1">However, in a multicenter observational study of inpatient treatment of pVT and VF in 889 patients younger than 18 years of age, administration of <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">amiodarone</a> (171 patients; 82 who also received <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">lidocaine</a>) was <strong>not</strong> associated with improved return of spontaneous circulation (ROSC), 24-hour survival, or survival to discharge [<a href="#rid72">72</a>]. Lidocaine administration (295 patients) was associated with significantly improved ROSC (adjusted odds ratio [aOR] 2) and 24-hour survival (aOR 1.7), but not improved survival to discharge. In a propensity-matched study of an in-hospital cardiac arrest (IHCA) registry, no difference was demonstrated in outcomes for children who received amiodarone compared with lidocaine for shock-refractory pVT and VF [<a href="#rid73">73</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and administration</strong> – <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">Amiodarone</a> may be given via rapid IV or intraosseous (IO) bolus in a dose of 5 mg/kg (maximum single dose, 300 mg). The 5 mg/kg dose may be repeated up to a maximum daily dose of 15 mg/kg (maximum recommended daily dose, 2.2 g) [<a href="#rid74">74</a>]. Alternatively, based upon a small case series, a 10 mg/kg per day continuous infusion appears safe and effective and may be started if there is a response to the initial bolus [<a href="#rid75">75</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">Amiodarone</a> should <strong>not</strong> be administered through an endotracheal tube (ETT).</p><p></p><p class="headingAnchor" id="H6659945"><span class="h2">Lidocaine</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">Lidocaine</a> may be used for the treatment of pulseless ventricular arrhythmias  (<a class="graphic graphic_table graphicRef70539" href="/z/d/graphic/70539.html" rel="external">table 1</a>). Either lidocaine or <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">amiodarone</a> is an appropriate medication for the initial treatment of shock-refractory ventricular arrhythmias in children. (See <a class="local">'Amiodarone'</a> above.) </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanisms</strong> – <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">Lidocaine</a> is a class IB antiarrhythmic that blocks sodium channels in cardiac conductive tissue when they are in the inactivated state at the end of depolarization and during early repolarization. This action results in inhibition of electrical conduction and automaticity, particularly in ischemic tissue [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indication and contraindications </strong>– <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">Lidocaine</a> is suggested for the treatment of pulseless ventricular arrhythmias that are refractory to high-quality cardiopulmonary resuscitation (CPR) defibrillation, and <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a>. Based upon the pediatric cardiac arrest algorithm  (<a class="graphic graphic_algorithm graphicRef129942" href="/z/d/graphic/129942.html" rel="external">algorithm 1</a>), <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">amiodarone</a> is <strong>not</strong> preferred over lidocaine for this indication [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1">In one multicenter observational study of 889 children younger than 18 years of age with inpatient treatment of pVT and VF, <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">lidocaine</a> administration (295 patients) was associated with improved ROSC and 24-hour survival, but not improved survival to discharge [<a href="#rid72">72</a>]. Thus, lidocaine or <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">amiodarone</a> are suggested for the treatment of shock-refractory ventricular arrhythmias. Further study is needed to demonstrate reproducibility of these results and generalizability to out-of-hospital settings. (See <a class="local">'Amiodarone'</a> above.)</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">Lidocaine</a> is <strong>contraindicated</strong> in patients with WPW syndrome and allergy to amide-type local anesthetics  (<a class="graphic graphic_table graphicRef57120" href="/z/d/graphic/57120.html" rel="external">table 6</a>). It may also cause seizures and myocardial and circulatory depression, especially in children with poor cardiac output or renal or liver failure [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/86747.html" rel="external">"Major side effects of class I antiarrhythmic drugs", section on 'Lidocaine (intravenous)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and administration</strong> – <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">Lidocaine</a> should be initially given as a single IV or IO bolus dose of 1 mg/kg followed by an infusion of 20 to 50 mcg/kg per minute. If the start of the infusion will be delayed longer than 15 minutes, then a second IV or IO bolus dose of 1 mg/kg is suggested.</p><p></p><p class="bulletIndent1">The initial bolus dose of <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">lidocaine</a> can be given by the endotracheal (ET) route, although IV or IO administration is strongly preferred. The suggested ET dose is 2 to 3 mg/kg. The technique for ET medication administration is discussed below. Studies evaluating the absorption of lidocaine by the ET route are lacking. (See <a class="local">'Endotracheal drug administration'</a> below.)</p><p></p><p class="headingAnchor" id="H8196901"><span class="h2">Magnesium sulfate</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="12982" href="/z/d/drug information/12982.html" rel="external">Magnesium sulfate</a> is the primary drug of choice for the treatment of torsades de pointes (TdP)  (<a class="graphic graphic_table graphicRef70539" href="/z/d/graphic/70539.html" rel="external">table 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanisms</strong> – Magnesium is a crucial cofactor in the sodium-potassium-ATPase enzyme system. It stabilizes the motor membrane by reducing the sensitivity of the motor end plate to acetylcholine. A decreased intracellular magnesium level promotes myocardial excitability but, even in the absence of a low magnesium level, a bolus of IV magnesium will suppress ectopic ventricular beats. At high levels, magnesium acts as a calcium channel blocker and can produce bradycardia with AV block and cardiac arrest. (See  <a class="medical medical_review" href="/z/d/html/831.html" rel="external">"Hypermagnesemia: Causes, symptoms, and treatment", section on 'Cardiovascular effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and contraindications</strong> – <a class="drug drug_pediatric" data-topicid="12982" href="/z/d/drug information/12982.html" rel="external">Magnesium sulfate</a> is indicated in the treatment of TdP (polymorphic VT with long QT interval) or documented hypomagnesemia. Patients with hypokalemia and arrhythmias frequently have associated hypomagnesemia. (See  <a class="medical medical_review" href="/z/d/html/1028.html" rel="external">"Supportive data for advanced cardiac life support in adults with sudden cardiac arrest", section on 'Magnesium sulfate'</a> and  <a class="medical medical_review" href="/z/d/html/848.html" rel="external">"Hypomagnesemia: Clinical manifestations of magnesium depletion", section on 'Hypokalemia'</a>.)</p><p></p><p class="bulletIndent1">Patients who receive <a class="drug drug_pediatric" data-topicid="12982" href="/z/d/drug information/12982.html" rel="external">magnesium sulfate</a> require monitoring of serum magnesium concentrations. Magnesium should be administered with caution to patients with myasthenia gravis or other neuromuscular disease and patients with renal impairment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and administration</strong> – For TdP, <a class="drug drug_pediatric" data-topicid="12982" href="/z/d/drug information/12982.html" rel="external">magnesium sulfate</a> should be diluted in 5 percent dextrose (D5W) to a 20 percent solution or less and given as an IV or IO infusion at a dose of 25 to 50 mg/kg (maximum dose: 2 g). The rate of infusion depends upon the clinical situation:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cardiac arrest – Infuse over one to two minutes.</p><p class="bulletIndent2"><span class="glyph">•</span>Perfusing rhythm – Infuse over 15 minutes because rapid infusion is associated with hypotension and asystole.</p><p></p><p class="headingAnchor" id="H4897390"><span class="h1">LIMITED INDICATIONS</span></p><p class="headingAnchor" id="H14"><span class="h2">Atropine</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="12875" href="/z/d/drug information/12875.html" rel="external">Atropine</a> is primarily indicated for vasovagal-induced bradycardia or the treatment of primary atrioventricular (AV) block  (<a class="graphic graphic_table graphicRef70539" href="/z/d/graphic/70539.html" rel="external">table 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanisms</strong> – <a class="drug drug_pediatric" data-topicid="12875" href="/z/d/drug information/12875.html" rel="external">Atropine</a> is a parasympatholytic drug that increases heart rate by accelerating the sinus and atrial pacemaker and improving conduction through the AV node. Although the dominant cardiac response is tachycardia, the heart rate may decrease transiently when small doses are administered [<a href="#rid76">76</a>]. This decrease is thought to occur because atropine, at low doses, blocks the M1 muscarinic postganglionic receptors that provide feedback inhibition for synaptic acetylcholine release [<a href="#rid77">77</a>]; the resulting increase in acetylcholine inhibits spontaneous impulse generation in the SA node.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and contraindications</strong> – <a class="drug drug_pediatric" data-topicid="12875" href="/z/d/drug information/12875.html" rel="external">Atropine</a> is recommended for children with bradycardia caused by increased vagal tone or primary AV block (ie, caused by factors intrinsic to the heart pacemaker, not secondary to extrinsic factors such as hypoxia, acidosis, hypotension, hypothermia, and drug effects) or unresponsive to oxygen, airway support, and administration of <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a>  (<a class="graphic graphic_algorithm graphicRef129941" href="/z/d/graphic/129941.html" rel="external">algorithm 3</a>) [<a href="#rid2">2,78-81</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12875" href="/z/d/drug information/12875.html" rel="external">Atropine</a> is no longer routinely recommended in children undergoing endotracheal (ET) intubation and is not recommended for pediatric patients with cardiac arrest  (<a class="graphic graphic_algorithm graphicRef129942" href="/z/d/graphic/129942.html" rel="external">algorithm 1</a>). However, it is suggested as a pre-treatment for rapid sequence intubation (RSI) in patients with (see  <a class="medical medical_review" href="/z/d/html/6390.html" rel="external">"Rapid sequence intubation (RSI) in children for emergency medicine: Approach", section on 'Pretreatment'</a>): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Septic or late-stage hypovolemic shock</p><p class="bulletIndent2"><span class="glyph">•</span>Children ≤5 years of age receiving <a class="drug drug_pediatric" data-topicid="12809" href="/z/d/drug information/12809.html" rel="external">succinylcholine</a> </p><p class="bulletIndent2"><span class="glyph">•</span>Children &gt;5 years of age requiring a second dose of <a class="drug drug_pediatric" data-topicid="12809" href="/z/d/drug information/12809.html" rel="external">succinylcholine</a> </p><p></p><p class="bulletIndent1">Furthermore, it is frequently used during RSI in infants &lt;1 year of age to counteract vagally-induced bradycardia. </p><p></p><p class="bulletIndent1">Sinus tachycardia may occur after administration of <a class="drug drug_pediatric" data-topicid="12875" href="/z/d/drug information/12875.html" rel="external">atropine</a>, but it usually is well tolerated in children. The development of hypoxia-induced bradycardia may be masked if atropine is given to block vagal-induced bradycardia during intubation. In these cases, the use of pulse oximetry is recommended to monitor oxygenation. (See  <a class="medical medical_review" href="/z/d/html/6390.html" rel="external">"Rapid sequence intubation (RSI) in children for emergency medicine: Approach", section on 'Pretreatment'</a>.)</p><p></p><p class="bulletIndent1">Fixed and dilated pupils should <strong>not</strong> be attributed to <a class="drug drug_pediatric" data-topicid="12875" href="/z/d/drug information/12875.html" rel="external">atropine</a> because atropine causes dilation of the pupils but does not eliminate the pupil constrictive response to light [<a href="#rid82">82</a>].</p><p></p><p class="bulletIndent1">When not being used in a resuscitation situation, <a class="drug drug_pediatric" data-topicid="12875" href="/z/d/drug information/12875.html" rel="external">atropine</a> is <strong>contraindicated</strong> in patients with obstructive gastrointestinal or genitourinary conditions (eg, surgical abdomen, paralytic ileus, posterior urethral valves), and myasthenia gravis (unless treating side effects of acetylcholinesterase inhibition) because it may exacerbate the underlying condition [<a href="#rid83">83</a>]. Atropine may cause additional tachycardia in patients with thyrotoxicosis and mucous plugging in patients with asthma. It should also be used with caution in patients with hyperthermia and delirium because of its central anticholinergic effects. (See  <a class="medical medical_review" href="/z/d/html/305.html" rel="external">"Anticholinergic poisoning"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and administration</strong> – The dose of <a class="drug drug_pediatric" data-topicid="12875" href="/z/d/drug information/12875.html" rel="external">atropine</a> varies depending on the route of administration. Although it can be given by the ET route, administration by the intravenous (IV) or the intraosseous (IO) route is preferred [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>IV/IO</strong> <strong>route</strong> – The recommended IV or IO dose of <a class="drug drug_pediatric" data-topicid="12875" href="/z/d/drug information/12875.html" rel="external">atropine</a> is 0.02 mg/kg. The maximum single dose is 1 mg. The dose may be repeated once if needed [<a href="#rid1">1</a>]. Higher doses are not routinely necessary because a total dose of 2 mg is sufficient to produce full vagal blockade in an adult [<a href="#rid84">84</a>].</p><p></p><p class="bulletIndent2">Patients with poisoning from cholinesterase-inhibiting agents may require much higher doses of <a class="drug drug_pediatric" data-topicid="12875" href="/z/d/drug information/12875.html" rel="external">atropine</a> to dry bronchial secretions. (See  <a class="medical medical_review" href="/z/d/html/339.html" rel="external">"Organophosphate and carbamate poisoning", section on 'Atropine'</a>.)</p><p></p><p class="bulletIndent2">In the 2015 update, the American Heart Association (AHA) Emergency Care Committee supports a weight-based dose of 0.02 mg/kg with no minimum dose when <a class="drug drug_pediatric" data-topicid="12875" href="/z/d/drug information/12875.html" rel="external">atropine</a> is given prior to ET intubation [<a href="#rid13">13,14,85</a>]. A prior study suggested a minimum parenteral dose of 0.1 mg because very low doses of atropine (0.0036 mg/kg) were associated with a mild slowing of heart rate [<a href="#rid76">76</a>]. This low dose effect was most evident in school-aged children. However, in neonates who weigh less than 5 kg, this minimum dose can lead to anticholinergic toxicity [<a href="#rid85">85,86</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>ET route</strong> – Studies evaluating the absorption of <a class="drug drug_pediatric" data-topicid="12875" href="/z/d/drug information/12875.html" rel="external">atropine</a> by the ET route are lacking. The recommended dose for ET administration is 0.04 to 0.06 mg/kg, which may also be repeated once [<a href="#rid1">1</a>]. The technique for ET medication administration is provided below. (See <a class="local">'Endotracheal drug administration'</a> below.)</p><p></p><p class="headingAnchor" id="H23"><span class="h2">Sodium bicarbonate</span><span class="headingEndMark"> — </span>The use of <a class="drug drug_pediatric" data-topicid="12795" href="/z/d/drug information/12795.html" rel="external">sodium bicarbonate</a> during pediatric resuscitation is limited to specific indications. The most effective means of correcting the acidosis in cardiac arrest is to provide adequate oxygenation, ventilation, and tissue perfusion. Because most pediatric cardiac arrests are caused by respiratory failure, support of ventilation through early intubation is the primary treatment, followed by support of the circulation with fluids and inotropic agents [<a href="#rid7">7</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanisms</strong> – <a class="drug drug_pediatric" data-topicid="12795" href="/z/d/drug information/12795.html" rel="external">Sodium bicarbonate</a> increases blood pH by buffering excess blood hydrogen ion as long as the patient has adequate ventilation to excrete carbon dioxide.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and contraindications</strong> –<strong> </strong><a class="drug drug_pediatric" data-topicid="12795" href="/z/d/drug information/12795.html" rel="external">Sodium bicarbonate</a> is recommended for the treatment of [<a href="#rid7">7,24,87,88</a>] (see  <a class="medical medical_review" href="/z/d/html/2332.html" rel="external">"Treatment and prevention of hyperkalemia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/295.html" rel="external">"Tricyclic antidepressant poisoning"</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Emergency treatment of hyperkalemia  (<a class="graphic graphic_table graphicRef85978" href="/z/d/graphic/85978.html" rel="external">table 7</a>) </p><p class="bulletIndent2"><span class="glyph">•</span>Hypermagnesemia </p><p class="bulletIndent2"><span class="glyph">•</span>Tricyclic antidepressant overdose or overdose from other sodium channel blocking agents and prolonged QRS duration or tachyarrhythmias </p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12795" href="/z/d/drug information/12795.html" rel="external">Sodium bicarbonate</a> may also be considered in children who have shock with documented metabolic acidosis that is not responsive to ventilatory support and adequate fluid resuscitation. (See  <a class="medical medical_review" href="/z/d/html/6395.html" rel="external">"Sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6389.html" rel="external">"Hypovolemic shock in children in resource-abundant settings: Initial evaluation and management", section on 'Fluid resuscitation'</a>.)</p><p></p><p class="bulletIndent1">For children with cardiac arrest who do <strong>not</strong> have the above conditions, the routine use of <a class="drug drug_pediatric" data-topicid="12795" href="/z/d/drug information/12795.html" rel="external">sodium bicarbonate</a> is <strong>not</strong> recommended because evidence suggests that the harm outweighs the benefit [<a href="#rid2">2,24,89-96</a>]. For example, in a propensity-matched cohort study of infants and children (median age 0.6 years) who received CPR in a pediatric intensive care unit (1100 patients), administration of sodium bicarbonate (528 children) was associated with lower survival to hospital discharge with favorable neurologic outcome (aOR 0.69, 95% CI 0.53-0.91) [<a href="#rid95">95</a>]. This lower survival among children receiving sodium bicarbonate during CPR is consistent with two other large observation studies [<a href="#rid94">94,96</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and administration </strong>– <a class="drug drug_pediatric" data-topicid="12795" href="/z/d/drug information/12795.html" rel="external">Sodium bicarbonate</a> is administered by the IV or IO route. It should <strong>not</strong> be given by the ET route because it is irritating to the airways, destroys lung surfactant, and can produce massive atelectasis [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1">The initial dose of <a class="drug drug_pediatric" data-topicid="12795" href="/z/d/drug information/12795.html" rel="external">sodium bicarbonate</a> is 1 mEq/kg (1 mL/kg of 8.4 percent solution or 2 mL/kg of 4.2 percent solution [recommended for children younger than six months of age]). The usual maximum single dose of sodium bicarbonate is 50 mEq for a child and 100 mEq for an adult.</p><p></p><p class="bulletIndent1">During prolonged cardiac arrest, subsequent doses of 0.5 mEq/kg each may be given every 10 minutes by slow (one to two minutes) infusion or based upon blood gas analysis [<a href="#rid1">1,7</a>]. However, arterial blood gas analysis taken during cardiac arrest or severe shock may overestimate tissue and venous pH. Thus, central venous blood gas measurements, if possible, are advised to accurately assess acid-base status during resuscitation [<a href="#rid97">97,98</a>].</p><p></p><p class="bulletIndent1">IV/IO tubing must be irrigated with normal <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">saline</a> before and after giving infusions of <a class="drug drug_pediatric" data-topicid="12795" href="/z/d/drug information/12795.html" rel="external">sodium bicarbonate</a> to prevent inactivation of administered <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> or, in hypocalcemic or hyperkalemic patients, precipitation with <a class="drug drug_pediatric" data-topicid="12651" href="/z/d/drug information/12651.html" rel="external">calcium chloride</a>. (See <a class="local">'Epinephrine'</a> above and <a class="local">'Calcium'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – <a class="drug drug_pediatric" data-topicid="12795" href="/z/d/drug information/12795.html" rel="external">Sodium bicarbonate</a> administration should <strong>not</strong> be given to children with inadequate ventilation because inadequate respiratory excretion of carbon dioxide will lead to retention and worsening respiratory acidosis [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1">Excess administration of <a class="drug drug_pediatric" data-topicid="12795" href="/z/d/drug information/12795.html" rel="external">sodium bicarbonate</a> during resuscitation has been associated with the following effects and should be avoided:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypertonicity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Worsening of intracellular acidosis with impairment of myocardial contractility.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Extreme metabolic alkalosis with reduced oxygen delivery to the tissues, hypokalemia, and decreased plasma ionized calcium concentration; all of these adverse effects increase the risk for arrhythmias.</p><p></p><p class="bulletIndent1">Repeated doses of <a class="drug drug_pediatric" data-topicid="12795" href="/z/d/drug information/12795.html" rel="external">sodium bicarbonate</a> can also produce symptomatic hypernatremia and hyperosmolarity [<a href="#rid99">99,100</a>]. Compared with plasma, the standard 8.4 percent sodium bicarbonate solution is hyperosmolar (2000 versus 289 mOsm/L) [<a href="#rid7">7</a>]. Use of hypertonic solutions in premature infants has been associated with an increased risk of developing periventricular-intraventricular hemorrhage [<a href="#rid101">101</a>]. For this reason, a more dilute solution (4.2 percent) should be used in infants younger than six months of age [<a href="#rid7">7,19,102</a>].</p><p></p><p class="bulletIndent1">The administration of <a class="drug drug_pediatric" data-topicid="12795" href="/z/d/drug information/12795.html" rel="external">sodium bicarbonate</a> may sclerose small veins and produces a chemical burn if extravasated into subcutaneous tissues [<a href="#rid7">7</a>]. Transient vasodilation and hypotension can occur with rapid infusion [<a href="#rid103">103</a>].</p><p></p><p class="headingAnchor" id="H4895656"><span class="h2">Calcium</span><span class="headingEndMark"> — </span>Calcium has limited uses in pediatric resuscitation, which include the treatment of hypocalcemia, hypermagnesemia, hyperkalemia, or calcium channel blocker overdose.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanisms</strong> – Calcium increases cardiac inotropy. Influx and efflux of calcium ions are important for the maintenance of normal conductivity and rhythm.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and contraindications</strong> – Calcium has a very specific indication in cardiac arrests as emergency protection against the arrhythmogenic effects of hypocalcemia, hyperkalemia, hypermagnesemia, or calcium channel blocker overdose [<a href="#rid1">1</a>]. It is otherwise not recommended for pediatric cardiac arrest because of an observed association with decreased survival and poor neurologic outcomes after pediatric arrests, including pediatric patients with heart disease [<a href="#rid2">2,104-108</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and administration </strong>– The optimum dose of calcium is based upon extrapolation from adult data and limited pediatric data. <a class="drug drug_pediatric" data-topicid="12651" href="/z/d/drug information/12651.html" rel="external">Calcium chloride</a> is preferred over <a class="drug drug_pediatric" data-topicid="12956" href="/z/d/drug information/12956.html" rel="external">calcium gluconate</a> because it provides greater bioavailability of calcium but should only be given if central venous access is available because administration through a peripheral IV line is associated with skin necrosis and sloughing [<a href="#rid109">109</a>]. Calcium gluconate is less irritating to the veins and may be administered by peripheral or central venous access.</p><p></p><p class="bulletIndent1">The recommended dose of elemental calcium is 5 to 7 mg/kg [<a href="#rid1">1</a>]. Dosing in this range can be achieved by giving 0.2 mL/kg of <a class="drug drug_pediatric" data-topicid="12651" href="/z/d/drug information/12651.html" rel="external">calcium chloride</a> 10%, which provides 5.4 mg/kg <strong>of elemental</strong> calcium or 0.6 mL/kg of <a class="drug drug_pediatric" data-topicid="12956" href="/z/d/drug information/12956.html" rel="external">calcium gluconate</a> 10%, which provides 5.6 mg/kg <strong>of elemental</strong> calcium. The maximum single dose is 540 mg <strong>of elemental</strong> calcium. Calcium chloride or calcium gluconate should be administered by slow IV push over 10 to 20 seconds in cardiac arrest and more slowly (eg, over 5 to 10 minutes) in perfusing patients.</p><p></p><p class="bulletIndent1">Rapid administration may cause bradycardia or asystole. If <a class="drug drug_pediatric" data-topicid="12795" href="/z/d/drug information/12795.html" rel="external">sodium bicarbonate</a> is being given through the same IV line, the tubing must be thoroughly flushed before and after calcium administration to prevent the formation of an insoluble precipitate in the catheter lumen.</p><p></p><p class="headingAnchor" id="H23863422"><span class="h1">ENDOTRACHEAL DRUG ADMINISTRATION</span><span class="headingEndMark"> — </span>Although lipid soluble drugs such as <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">lidocaine</a>, <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a>, <a class="drug drug_pediatric" data-topicid="12875" href="/z/d/drug information/12875.html" rel="external">atropine</a>, and <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">naloxone</a> ("LEAN") may be administered via an endotracheal tube (ETT), the intravascular route is always preferred [<a href="#rid13">13,14</a>]. Optimal drug dosing via ETT is unknown for many medications. Unpredictable drug absorption may lead to lower blood levels when compared with the same dose given by an intravascular route.</p><p></p><p>Several key actions are needed when giving drugs via an ETT:</p><p class="bulletIndent1"><span class="glyph">●</span>Increase the <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> dose 10-fold and the dose of other medications (<a class="drug drug_pediatric" data-topicid="12875" href="/z/d/drug information/12875.html" rel="external">atropine</a>, <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">lidocaine</a>, <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">naloxone</a>) two- to threefold. (See <a class="local">'Epinephrine'</a> above and <a class="local">'Atropine'</a> above and  <a class="medical medical_review" href="/z/d/html/6504.html" rel="external">"Opioid intoxication in children and adolescents", section on 'Dosing and administration'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hold compressions during ETT administration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dilute the medication in normal <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">saline</a> to a volume of 3 to 5 mL and instill into the ETT or beyond the tip of the ETT with a suction catheter.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Follow drug administration with a 3 to 5 mL flush of normal <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">saline</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Provide five positive pressure ventilations (typically five breaths) after instilling the drug.</p><p></p><p class="headingAnchor" id="H2385361018"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117107.html" rel="external">"Society guideline links: Basic and advanced cardiac life support in children"</a>.)</p><p class="headingAnchor" id="H5953323"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of medications in pediatric advanced life support (PALS)</strong> – In children undergoing PALS, medications are of secondary importance to the prompt treatment of hypoxemia and respiratory failure, and initiation of high-quality basic life support (BLS), including (see  <a class="medical medical_review" href="/z/d/html/6392.html" rel="external">"Pediatric advanced life support (PALS)"</a>): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cardiopulmonary resuscitation (CPR)</strong> – In patients with cardiac arrest or bradycardia with poor perfusion (see  <a class="medical medical_review" href="/z/d/html/6384.html" rel="external">"Pediatric basic life support (BLS) for health care providers", section on 'Basic life support approach'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Defibrillation</strong> – In patients with pulseless ventricular arrhythmias (ventricular fibrillation [VF], pulseless ventricular tachycardia [pVT], or torsades de pointes [TdP]) (see  <a class="medical medical_review" href="/z/d/html/6311.html" rel="external">"Technique of defibrillation and cardioversion in children (including automated external defibrillation)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug therapy by clinical condition</strong> – Pharmacologic agents with their indications and dosing for children undergoing PALS are provided in the table  (<a class="graphic graphic_table graphicRef70539" href="/z/d/graphic/70539.html" rel="external">table 1</a>). The primary drugs used in PALS, according to clinical presentation, are (see <a class="local">'Drug therapy by clinical condition'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypoxemia</strong> – Oxygen.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypoglycemia</strong> – Dextrose (glucose).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cardiac arrest with nonshockable rhythm (asystole or pulseless electrical activity [PEA])</strong> – Oxygen, <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> as adjuncts to high-quality CPR  (<a class="graphic graphic_algorithm graphicRef129942" href="/z/d/graphic/129942.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cardiac arrest with shockable rhythm (VF, pVT, or TdP)</strong> – Oxygen, <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a>, and as adjuncts to high-quality CPR and defibrillation:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For VF and pVT, <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">lidocaine</a> or <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">amiodarone</a>  (<a class="graphic graphic_algorithm graphicRef129942" href="/z/d/graphic/129942.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent3"><span class="glyph">-</span>For TdP, <a class="drug drug_pediatric" data-topicid="12982" href="/z/d/drug information/12982.html" rel="external">magnesium sulfate</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cardiac arrest associated with hyperkalemia or sodium channel blocker (eg, tricyclic antidepressant) overdose </strong>– In addition to the medications above, <a class="drug drug_pediatric" data-topicid="12795" href="/z/d/drug information/12795.html" rel="external">sodium bicarbonate</a>; severe hyperkalemia can also cause asystole or PEA.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Narrow-complex tachycardia (supraventricular tachycardia [SVT])</strong> – Oxygen, <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a>, and, in consultation with a pediatric cardiologist, <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">amiodarone</a> or <a class="drug drug_pediatric" data-topicid="12732" href="/z/d/drug information/12732.html" rel="external">procainamide</a> as adjuncts to indicated vagal maneuvers and synchronized cardioversion  (<a class="graphic graphic_algorithm graphicRef129940" href="/z/d/graphic/129940.html" rel="external">algorithm 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Wide-complex tachycardia (ventricular tachycardia [VT] or aberrant SVT)</strong> – Oxygen, and as adjuncts to indicated synchronized cardioversion  (<a class="graphic graphic_algorithm graphicRef129940" href="/z/d/graphic/129940.html" rel="external">algorithm 2</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For VT, and in consultation with a pediatric cardiologist, <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">lidocaine</a> or <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">amiodarone</a>.</p><p class="bulletIndent3"><span class="glyph">-</span>For aberrant SVT, <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a>; if adenosine is unsuccessful and, in consultation with a pediatric cardiologist, <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">amiodarone</a> or <a class="drug drug_pediatric" data-topicid="12732" href="/z/d/drug information/12732.html" rel="external">procainamide</a>. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bradycardia with poor perfusion</strong> – Oxygen, <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a>, and, for patients with increased vagal tone, primary atrioventricular (AV) block, or unresponsive to epinephrine, <a class="drug drug_pediatric" data-topicid="12875" href="/z/d/drug information/12875.html" rel="external">atropine</a> as adjuncts to high-quality CPR (for heart rate &lt;60 per minute)  (<a class="graphic graphic_algorithm graphicRef129941" href="/z/d/graphic/129941.html" rel="external">algorithm 3</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fluid-refractory</strong> <strong>septic shock </strong>–<strong> </strong>First-line agents: <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> or norepinephrine; indications and dosing are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/85767.html" rel="external">"Septic shock in children in resource-abundant settings: Rapid recognition and initial resuscitation (first hour)", section on 'Patients with fluid-refractory shock'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypocalcemia, hypermagnesemia, hyperkalemia or calcium channel blocker overdose</strong> – For patients with significant electrocardiogram (ECG) changes, <a class="drug drug_pediatric" data-topicid="12651" href="/z/d/drug information/12651.html" rel="external">calcium chloride</a> or <a class="drug drug_pediatric" data-topicid="12956" href="/z/d/drug information/12956.html" rel="external">calcium gluconate</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypomagnesemia or torsades de pointes</strong> <strong>(TdP)</strong> – <a class="drug drug_pediatric" data-topicid="12982" href="/z/d/drug information/12982.html" rel="external">Magnesium sulfate</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Opioid intoxication</strong> – The use of <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">naloxone</a> for children with suspected opioid intoxication and clinical findings of coma, depressed respirations, and/or miosis is discussed in the table  (<a class="graphic graphic_table graphicRef69375" href="/z/d/graphic/69375.html" rel="external">table 2</a>) and provided separately. (See  <a class="medical medical_review" href="/z/d/html/6504.html" rel="external">"Opioid intoxication in children and adolescents", section on 'Naloxone'</a>.)</p><p></p><p class="headingAnchor" id="H2294319993"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Pamela Bailey, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S876.</a></li><li><a class="nounderline abstract_t">Topjian AA, Raymond TT, Atkins D, et al. Part 4: Pediatric Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2020; 142:S469.</a></li><li><a class="nounderline abstract_t">Bennett KS, Clark AE, Meert KL, et al. Early oxygenation and ventilation measurements after pediatric cardiac arrest: lack of association with outcome. Crit Care Med 2013; 41:1534.</a></li><li><a class="nounderline abstract_t">López-Herce J, del Castillo J, Matamoros M, et al. Post return of spontaneous circulation factors associated with mortality in pediatric in-hospital cardiac arrest: a prospective multicenter multinational observational study. Crit Care 2014; 18:607.</a></li><li><a class="nounderline abstract_t">Ferguson LP, Durward A, Tibby SM. Relationship between arterial partial oxygen pressure after resuscitation from cardiac arrest and mortality in children. Circulation 2012; 126:335.</a></li><li><a class="nounderline abstract_t">Del Castillo J, López-Herce J, Matamoros M, et al. Hyperoxia, hypocapnia and hypercapnia as outcome factors after cardiac arrest in children. Resuscitation 2012; 83:1456.</a></li><li class="breakAll">Pediatric Advanced Life Support Provider Manual, American  Heart Association, Dallas 2020. p.204.</li><li><a class="nounderline abstract_t">Michaud LJ, Rivara FP, Longstreth WT Jr, Grady MS. Elevated initial blood glucose levels and poor outcome following severe brain injuries in children. J Trauma 1991; 31:1356.</a></li><li><a class="nounderline abstract_t">Srinivasan V, Spinella PC, Drott HR, et al. Association of timing, duration, and intensity of hyperglycemia with intensive care unit mortality in critically ill children. Pediatr Crit Care Med 2004; 5:329.</a></li><li><a class="nounderline abstract_t">Kong MY, Alten J, Tofil N. Is hyperglycemia really harmful? A critical appraisal of "Persistent hyperglycemia in critically ill children" by Faustino and Apkon (J Pediatr 2005; 146:30-34). Pediatr Crit Care Med 2007; 8:482.</a></li><li><a class="nounderline abstract_t">Blanco CL, Kim J. Neonatal Glucose Homeostasis. Clin Perinatol 2022; 49:393.</a></li><li><a class="nounderline abstract_t">Paulsen ME, Rao RB. Cerebral Effects of Neonatal Dysglycemia. Clin Perinatol 2022; 49:405.</a></li><li class="breakAll">American Heart Association. Web-based Integrated Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care - Part 11: Pediatric Basic Life Support and Cardiopulmonary Resuscitation Quality. ECCguidelines.heart.org (Accessed on October 15, 2015).</li><li><a class="nounderline abstract_t">Atkins DL, Berger S, Duff JP, et al. Part 11: Pediatric Basic Life Support and Cardiopulmonary Resuscitation Quality: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2015; 132:S519.</a></li><li><a class="nounderline abstract_t">Paradis NA, Koscove EM. Epinephrine in cardiac arrest: a critical review. Ann Emerg Med 1990; 19:1288.</a></li><li><a class="nounderline abstract_t">Goetting MG, Paradis NA. High-dose epinephrine improves outcome from pediatric cardiac arrest. Ann Emerg Med 1991; 20:22.</a></li><li><a class="nounderline abstract_t">Paradis NA, Martin GB, Rivers EP, et al. Coronary perfusion pressure and the return of spontaneous circulation in human cardiopulmonary resuscitation. JAMA 1990; 263:1106.</a></li><li><a class="nounderline abstract_t">Michael JR, Guerci AD, Koehler RC, et al. Mechanisms by which epinephrine augments cerebral and myocardial perfusion during cardiopulmonary resuscitation in dogs. Circulation 1984; 69:822.</a></li><li class="breakAll">Ludwig S, Lavelle JM. Resuscitation-pediatric basic and advanced life support. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.3.</li><li><a class="nounderline abstract_t">Otto CW, Yakaitis RW, Blitt CD. Mechanism of action of epinephrine in resuscitation from asphyxial arrest. Crit Care Med 1981; 9:321.</a></li><li><a class="nounderline abstract_t">Weiss SL, Peters MJ, Alhazzani W, et al. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Intensive Care Med 2020; 46:10.</a></li><li><a class="nounderline abstract_t">Holmberg MJ, Ross CE, Yankama T, et al. Epinephrine in children receiving cardiopulmonary resuscitation for bradycardia with poor perfusion. Resuscitation 2020; 149:180.</a></li><li><a class="nounderline abstract_t">Khera R, Tang Y, Girotra S, et al. Pulselessness After Initiation of Cardiopulmonary Resuscitation for Bradycardia in Hospitalized Children. Circulation 2019; 140:370.</a></li><li><a class="nounderline abstract_t">Kleinman ME, de Caen AR, Chameides L, et al. Pediatric basic and advanced life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. Pediatrics 2010; 126:e1261.</a></li><li><a class="nounderline abstract_t">Enright K, Turner C, Roberts P, et al. Primary cardiac arrest following sport or exertion in children presenting to an emergency department: chest compressions and early defibrillation can save lives, but is intravenous epinephrine always appropriate? Pediatr Emerg Care 2012; 28:336.</a></li><li><a class="nounderline abstract_t">Niemann JT, Stratton SJ. Endotracheal versus intravenous epinephrine and atropine in out-of-hospital "primary" and postcountershock asystole. Crit Care Med 2000; 28:1815.</a></li><li><a class="nounderline abstract_t">Niemann JT, Stratton SJ, Cruz B, Lewis RJ. Endotracheal drug administration during out-of-hospital resuscitation: where are the survivors? Resuscitation 2002; 53:153.</a></li><li><a class="nounderline abstract_t">Andersen LW, Berg KM, Saindon BZ, et al. Time to Epinephrine and Survival After Pediatric In-Hospital Cardiac Arrest. JAMA 2015; 314:802.</a></li><li><a class="nounderline abstract_t">Lin YR, Wu MH, Chen TY, et al. Time to epinephrine treatment is associated with the risk of mortality in children who achieve sustained ROSC after traumatic out-of-hospital cardiac arrest. Crit Care 2019; 23:101.</a></li><li><a class="nounderline abstract_t">Lin YR, Li CJ, Huang CC, et al. Early Epinephrine Improves the Stabilization of Initial Post-resuscitation Hemodynamics in Children With Non-shockable Out-of-Hospital Cardiac Arrest. Front Pediatr 2019; 7:220.</a></li><li><a class="nounderline abstract_t">Fukuda T, Kondo Y, Hayashida K, et al. Time to epinephrine and survival after paediatric out-of-hospital cardiac arrest. Eur Heart J Cardiovasc Pharmacother 2018; 4:144.</a></li><li><a class="nounderline abstract_t">Hansen M, Schmicker RH, Newgard CD, et al. Time to Epinephrine Administration and Survival From Nonshockable Out-of-Hospital Cardiac Arrest Among Children and Adults. Circulation 2018; 137:2032.</a></li><li><a class="nounderline abstract_t">Meert K, Telford R, Holubkov R, et al. Paediatric in-hospital cardiac arrest: Factors associated with survival and neurobehavioural outcome one year later. Resuscitation 2018; 124:96.</a></li><li><a class="nounderline abstract_t">Hoyme DB, Patel SS, Samson RA, et al. Epinephrine dosing interval and survival outcomes during pediatric in-hospital cardiac arrest. Resuscitation 2017; 117:18.</a></li><li class="breakAll">US Food &amp; Drug Administration. Important Labeling Changes to Critical Care Medications. https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm562565.htm (Accessed on October 10, 2017).</li><li><a class="nounderline abstract_t">Kienzle MF, Morgan RW, Faerber JA, et al. The Effect of Epinephrine Dosing Intervals on Outcomes from Pediatric In-Hospital Cardiac Arrest. Am J Respir Crit Care Med 2021; 204:977.</a></li><li><a class="nounderline abstract_t">Matsuyama T, Komukai S, Izawa J, et al. Pre-Hospital Administration of Epinephrine in Pediatric Patients With Out-of-Hospital Cardiac Arrest. J Am Coll Cardiol 2020; 75:194.</a></li><li><a class="nounderline abstract_t">Perondi MB, Reis AG, Paiva EF, et al. A comparison of high-dose and standard-dose epinephrine in children with cardiac arrest. N Engl J Med 2004; 350:1722.</a></li><li><a class="nounderline abstract_t">Dieckmann RA, Vardis R. High-dose epinephrine in pediatric out-of-hospital cardiopulmonary arrest. Pediatrics 1995; 95:901.</a></li><li><a class="nounderline abstract_t">Carpenter TC, Stenmark KR. High-dose epinephrine is not superior to standard-dose epinephrine in pediatric in-hospital cardiopulmonary arrest. Pediatrics 1997; 99:403.</a></li><li><a class="nounderline abstract_t">Zaritsky A. Pediatric resuscitation pharmacology. Members of the Medications in Pediatric Resuscitation Panel. Ann Emerg Med 1993; 22:445.</a></li><li><a class="nounderline abstract_t">Guidelines for cardiopulmonary resuscitation and emergency cardiac care. Emergency Cardiac Care Committee and Subcommittees, American Heart Association. Part VII. Neonatal resuscitation. JAMA 1992; 268:2276.</a></li><li><a class="nounderline abstract_t">American Heart Association. Management of cardiac arrest. Circulation 2005; 112:IV.</a></li><li><a class="nounderline abstract_t">Haft JI. Cardiovascular injury induced by sympathetic catecholamines. Prog Cardiovasc Dis 1974; 17:73.</a></li><li><a class="nounderline abstract_t">Rivers EP, Wortsman J, Rady MY, et al. The effect of the total cumulative epinephrine dose administered during human CPR on hemodynamic, oxygen transport, and utilization variables in the postresuscitation period. Chest 1994; 106:1499.</a></li><li><a class="nounderline abstract_t">Guidelines for cardiopulmonary resuscitation and emergency cardiac care. Emergency Cardiac Care Committee and Subcommittees, American Heart Association. Part VI. Pediatric advanced life support. JAMA 1992; 268:2262.</a></li><li><a class="nounderline abstract_t">Stroumpoulis K, Xanthos T, Rokas G, et al. Vasopressin and epinephrine in the treatment of cardiac arrest: an experimental study. Crit Care 2008; 12:R40.</a></li><li><a class="nounderline abstract_t">Jing XL, Li X, Li H, et al. Vasopressin and epinephrine versus epinephrine in management of patients with cardiac arrest: a meta-analysis. Signa Vitae 2010; 5:20.</a></li><li><a class="nounderline abstract_t">Sheriff A, Rameshkumar R, Chidambaram M, et al. Epinephrine Plus Vasopressin vs Epinephrine Plus Placebo in Pediatric Intensive Care Unit Cardiopulmonary Resuscitation: A Randomized Double Blind Controlled Clinical Trial. Indian Pediatr 2021; 58:624.</a></li><li><a class="nounderline abstract_t">Duncan JM, Meaney P, Simpson P, et al. Vasopressin for in-hospital pediatric cardiac arrest: results from the American Heart Association National Registry of Cardiopulmonary Resuscitation. Pediatr Crit Care Med 2009; 10:191.</a></li><li><a class="nounderline abstract_t">Campbell M, Buitrago SR. BET 2: Ice water immersion, other vagal manoeuvres or adenosine for SVT in children. Emerg Med J 2017; 34:58.</a></li><li><a class="nounderline abstract_t">Clausen H, Theophilos T, Jackno K, Babl FE. Paediatric arrhythmias in the emergency department. Emerg Med J 2012; 29:732.</a></li><li><a class="nounderline abstract_t">Díaz-Parra S, Sánchez-Yañez P, Zabala-Argüelles I, et al. Use of adenosine in the treatment of supraventricular tachycardia in a pediatric emergency department. Pediatr Emerg Care 2014; 30:388.</a></li><li><a class="nounderline abstract_t">Chu PY, Hill KD, Clark RH, et al. Treatment of supraventricular tachycardia in infants: Analysis of a large multicenter database. Early Hum Dev 2015; 91:345.</a></li><li><a class="nounderline abstract_t">Lewis J, Arora G, Tudorascu DL, et al. Acute Management of Refractory and Unstable Pediatric Supraventricular Tachycardia. J Pediatr 2017; 181:177.</a></li><li><a class="nounderline abstract_t">Borquez AA, Aljohani OA, Williams MR, Perry JC. Intravenous Sotalol in the Young: Safe and Effective Treatment With Standardized Protocols. JACC Clin Electrophysiol 2020; 6:425.</a></li><li><a class="nounderline abstract_t">Appelboam A, Reuben A, Mann C, et al. Postural modification to the standard Valsalva manoeuvre for emergency treatment of supraventricular tachycardias (REVERT): a randomised controlled trial. Lancet 2015; 386:1747.</a></li><li><a class="nounderline abstract_t">Bronzetti G, Brighenti M, Mariucci E, et al. Upside-down position for the out of hospital management of children with supraventricular tachycardia. Int J Cardiol 2018; 252:106.</a></li><li><a class="nounderline abstract_t">Chang PM, Silka MJ, Moromisato DY, Bar-Cohen Y. Amiodarone versus procainamide for the acute treatment of recurrent supraventricular tachycardia in pediatric patients. Circ Arrhythm Electrophysiol 2010; 3:134.</a></li><li><a class="nounderline abstract_t">Sacchetti A, Moyer V, Baricella R, et al. Primary cardiac arrhythmias in children. Pediatr Emerg Care 1999; 15:95.</a></li><li><a class="nounderline abstract_t">Quail MA, Till J. Question 3 Does a higher initial dose of adenosine improve cardioversion rates in supraventricular tachycardia? Arch Dis Child 2012; 97:177.</a></li><li><a class="nounderline abstract_t">Moffett BS, Cannon BC, Friedman RA, Kertesz NJ. Therapeutic levels of intravenous procainamide in neonates: a retrospective assessment. Pharmacotherapy 2006; 26:1687.</a></li><li><a class="nounderline abstract_t">Richardson C, Silver ES. Management of Supraventricular Tachycardia in Infants. Paediatr Drugs 2017; 19:539.</a></li><li><a class="nounderline abstract_t">Shenoi RP, Timm N, COMMITTEE ON DRUGS, COMMITTEE ON PEDIATRIC EMERGENCY MEDICINE. Drugs Used to Treat Pediatric Emergencies. Pediatrics 2020; 145.</a></li><li><a class="nounderline abstract_t">Luedtke SA, Kuhn RJ, McCaffrey FM. Pharmacologic management of supraventricular tachycardias in children. Part 2: Atrial flutter, atrial fibrillation, and junctional and atrial ectopic tachycardia. Ann Pharmacother 1997; 31:1347.</a></li><li class="breakAll">American Heart Association. Web-based Integrated Guidelines for Cardiopulmonary and Emergency Cardiovascular Care - Part 12. Pediatric advanced life support. https://eccguidelines.heart.org/index.php/circulation/cpr-ecc-guidelines-2/part-12-pediatric-advanced-life-support/ (Accessed on November 10, 2015).</li><li><a class="nounderline abstract_t">de Caen AR, Berg MD, Chameides L, et al. Part 12: Pediatric Advanced Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2015; 132:S526.</a></li><li><a class="nounderline abstract_t">Soar J, Donnino MW, Maconochie I, et al. 2018 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations Summary. Circulation 2018; 138:e714.</a></li><li><a class="nounderline abstract_t">Duff JP, Topjian A, Berg MD, et al. 2018 American Heart Association Focused Update on Pediatric Advanced Life Support: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2018; 138:e731.</a></li><li><a class="nounderline abstract_t">Fishberger SB, Hannan RL, Welch EM, Rossi AF. Amiodarone for pediatric resuscitation: a word of caution. Pediatr Cardiol 2009; 30:1006.</a></li><li><a class="nounderline abstract_t">Perry JC, Fenrich AL, Hulse JE, et al. Pediatric use of intravenous amiodarone: efficacy and safety in critically ill patients from a multicenter protocol. J Am Coll Cardiol 1996; 27:1246.</a></li><li><a class="nounderline abstract_t">Valdes SO, Donoghue AJ, Hoyme DB, et al. Outcomes associated with amiodarone and lidocaine in the treatment of in-hospital pediatric cardiac arrest with pulseless ventricular tachycardia or ventricular fibrillation. Resuscitation 2014; 85:381.</a></li><li><a class="nounderline abstract_t">Holmberg MJ, Ross CE, Atkins DL, et al. Lidocaine versus amiodarone for pediatric in-hospital cardiac arrest: An observational study. Resuscitation 2020; 149:191.</a></li><li><a class="nounderline abstract_t">Saul JP, Scott WA, Brown S, et al. Intravenous amiodarone for incessant tachyarrhythmias in children: a randomized, double-blind, antiarrhythmic drug trial. Circulation 2005; 112:3470.</a></li><li><a class="nounderline abstract_t">Ramusovic S, Läer S, Meibohm B, et al. Pharmacokinetics of intravenous amiodarone in children. Arch Dis Child 2013; 98:989.</a></li><li><a class="nounderline abstract_t">Dauchot P, Gravenstein JS. Effects of atropine on the electrocardiogram in different age groups. Clin Pharmacol Ther 1971; 12:274.</a></li><li><a class="nounderline abstract_t">Todd GL, Baroldi G, Pieper GM, et al. Experimental catecholamine-induced myocardial necrosis. I. Morphology, quantification and regional distribution of acute contraction band lesions. J Mol Cell Cardiol 1985; 17:317.</a></li><li><a class="nounderline abstract_t">Smith I, Monk TG, White PF. Comparison of transesophageal atrial pacing with anticholinergic drugs for the treatment of intraoperative bradycardia. Anesth Analg 1994; 78:245.</a></li><li><a class="nounderline abstract_t">Brady WJ, Swart G, DeBehnke DJ, et al. The efficacy of atropine in the treatment of hemodynamically unstable bradycardia and atrioventricular block: prehospital and emergency department considerations. Resuscitation 1999; 41:47.</a></li><li><a class="nounderline abstract_t">Zimmerman G, Steward DJ. Bradycardia delays the onset of action of intravenous atropine in infants. Anesthesiology 1986; 65:320.</a></li><li><a class="nounderline abstract_t">Fullerton DA, St Cyr JA, Clarke DR, et al. Bezold-Jarisch reflex in postoperative pediatric cardiac surgical patients. Ann Thorac Surg 1991; 52:534.</a></li><li><a class="nounderline abstract_t">Goetting MG, Contreras E. Systemic atropine administration during cardiac arrest does not cause fixed and dilated pupils. Ann Emerg Med 1991; 20:55.</a></li><li class="breakAll">Atropine. In: Martindale: The Complete Drug Reference, Sweetman SC (Ed), Pharmaceutical Press, London. Electronic version 2011.</li><li><a class="nounderline abstract_t">O'Rourke GW, Greene NM. Autonomic blockade and the resting heart rate in man. Am Heart J 1970; 80:469.</a></li><li><a class="nounderline abstract_t">Barrington KJ. The myth of a minimum dose for atropine. Pediatrics 2011; 127:783.</a></li><li><a class="nounderline abstract_t">Barrington KJ, Byrne PJ. Premedication for neonatal intubation. Am J Perinatol 1998; 15:213.</a></li><li><a class="nounderline abstract_t">Ettinger PO, Regan TJ, Oldewurtel HA. Hyperkalemia, cardiac conduction, and the electrocardiogram: a review. Am Heart J 1974; 88:360.</a></li><li><a class="nounderline abstract_t">Hoffman JR, Votey SR, Bayer M, Silver L. Effect of hypertonic sodium bicarbonate in the treatment of moderate-to-severe cyclic antidepressant overdose. Am J Emerg Med 1993; 11:336.</a></li><li><a class="nounderline abstract_t">Matamoros M, Rodriguez R, Callejas A, et al. In-hospital pediatric cardiac arrest in Honduras. Pediatr Emerg Care 2015; 31:31.</a></li><li><a class="nounderline abstract_t">Nehme Z, Namachivayam S, Forrest A, et al. Trends in the incidence and outcome of paediatric out-of-hospital cardiac arrest: A 17-year observational study. Resuscitation 2018; 128:43.</a></li><li><a class="nounderline abstract_t">López-Herce J, del Castillo J, Cañadas S, et al. In-hospital pediatric cardiac arrest in Spain. Rev Esp Cardiol (Engl Ed) 2014; 67:189.</a></li><li><a class="nounderline abstract_t">Wolfe HA, Sutton RM, Reeder RW, et al. Functional outcomes among survivors of pediatric in-hospital cardiac arrest are associated with baseline neurologic and functional status, but not with diastolic blood pressure during CPR. Resuscitation 2019; 143:57.</a></li><li><a class="nounderline abstract_t">Del Castillo J, López-Herce J, Cañadas S, et al. Cardiac arrest and resuscitation in the pediatric intensive care unit: a prospective multicenter multinational study. Resuscitation 2014; 85:1380.</a></li><li><a class="nounderline abstract_t">Chang CY, Wu PH, Hsiao CT, et al. Sodium bicarbonate administration during in-hospital pediatric cardiac arrest: A systematic review and meta-analysis. Resuscitation 2021; 162:188.</a></li><li><a class="nounderline abstract_t">Cashen K, Reeder RW, Ahmed T, et al. Sodium Bicarbonate Use During Pediatric Cardiopulmonary Resuscitation: A Secondary Analysis of the ICU-RESUScitation Project Trial. Pediatr Crit Care Med 2022; 23:784.</a></li><li><a class="nounderline abstract_t">Loomba RS, Ahmed M, Abdulkarim M, et al. Use of Sodium Bicarbonate During Pediatric Cardiac Admissions with Cardiac Arrest: Who Gets It and What Does It Do? Children (Basel) 2019; 6.</a></li><li><a class="nounderline abstract_t">Weil MH, Rackow EC, Trevino R, et al. Difference in acid-base state between venous and arterial blood during cardiopulmonary resuscitation. N Engl J Med 1986; 315:153.</a></li><li><a class="nounderline abstract_t">Steedman DJ, Robertson CE. Acid base changes in arterial and central venous blood during cardiopulmonary resuscitation. Arch Emerg Med 1992; 9:169.</a></li><li><a class="nounderline abstract_t">Máttar JA, Weil MH, Shubin H, Stein L. Cardiac arrest in the critically ill. II. Hyperosmolal states following cardiac arrest. Am J Med 1974; 56:162.</a></li><li><a class="nounderline abstract_t">Aufderheide TP, Martin DR, Olson DW, et al. Prehospital bicarbonate use in cardiac arrest: a 3-year experience. Am J Emerg Med 1992; 10:4.</a></li><li><a class="nounderline abstract_t">Howell JH. Sodium bicarbonate in the perinatal setting--revisited. Clin Perinatol 1987; 14:807.</a></li><li><a class="nounderline abstract_t">Ushay HM, Notterman DA. Pharmacology of pediatric resuscitation. Pediatr Clin North Am 1997; 44:207.</a></li><li><a class="nounderline abstract_t">Coté CJ, Greenhow DE, Marshall BE. The hypotensive response to rapid intravenous administration of hypertonic solutions in man and in the rabbit. Anesthesiology 1979; 50:30.</a></li><li><a class="nounderline abstract_t">Srinivasan V, Morris MC, Helfaer MA, et al. Calcium use during in-hospital pediatric cardiopulmonary resuscitation: a report from the National Registry of Cardiopulmonary Resuscitation. Pediatrics 2008; 121:e1144.</a></li><li><a class="nounderline abstract_t">Kette F, Ghuman J, Parr M. Calcium administration during cardiac arrest:  a systematic review. Eur J Emerg Med 2013; 20:72.</a></li><li><a class="nounderline abstract_t">Lasa JJ, Alali A, Minard CG, et al. Cardiopulmonary Resuscitation in the Pediatric Cardiac Catheterization Laboratory: A Report From the American Heart Association's Get With the Guidelines-Resuscitation Registry. Pediatr Crit Care Med 2019; 20:1040.</a></li><li><a class="nounderline abstract_t">Mok YH, Loke AP, Loh TF, Lee JH. Characteristics and Risk Factors for Mortality in Paediatric In-Hospital Cardiac Events in Singapore: Retrospective Single Centre Experience. Ann Acad Med Singap 2016; 45:534.</a></li><li><a class="nounderline abstract_t">Dhillon GS, Kleinman ME, Staffa SJ, et al. Calcium Administration During Cardiopulmonary Resuscitation for In-Hospital Cardiac Arrest in Children With Heart Disease Is Associated With Worse Survival-A Report From the American Heart Association's Get With The Guidelines-Resuscitation (GWTG-R) Registry. Pediatr Crit Care Med 2022; 23:860.</a></li><li><a class="nounderline abstract_t">Broner CW, Stidham GL, Westenkirchner DF, Watson DC. A prospective, randomized, double-blind comparison of calcium chloride and calcium gluconate therapies for hypocalcemia in critically ill children. J Pediatr 1990; 117:986.</a></li></ol></div><div id="topicVersionRevision">Topic 6386 Version 42.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20956230" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33081526" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Part 4: Pediatric Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23552509" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Early oxygenation and ventilation measurements after pediatric cardiac arrest: lack of association with outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25672247" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Post return of spontaneous circulation factors associated with mortality in pediatric in-hospital cardiac arrest: a prospective multicenter multinational observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22723307" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Relationship between arterial partial oxygen pressure after resuscitation from cardiac arrest and mortality in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22841610" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Hyperoxia, hypocapnia and hypercapnia as outcome factors after cardiac arrest in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22841610" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Hyperoxia, hypocapnia and hypercapnia as outcome factors after cardiac arrest in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1942143" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Elevated initial blood glucose levels and poor outcome following severe brain injuries in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15215001" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Association of timing, duration, and intensity of hyperglycemia with intensive care unit mortality in critically ill children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17693916" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Is hyperglycemia really harmful? A critical appraisal of "Persistent hyperglycemia in critically ill children" by Faustino and Apkon (J Pediatr 2005; 146:30-34).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35659093" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Neonatal Glucose Homeostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35659094" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cerebral Effects of Neonatal Dysglycemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35659094" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cerebral Effects of Neonatal Dysglycemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26472999" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Part 11: Pediatric Basic Life Support and Cardiopulmonary Resuscitation Quality: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2240726" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Epinephrine in cardiac arrest: a critical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1984722" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : High-dose epinephrine improves outcome from pediatric cardiac arrest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2386557" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Coronary perfusion pressure and the return of spontaneous circulation in human cardiopulmonary resuscitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6697465" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Mechanisms by which epinephrine augments cerebral and myocardial perfusion during cardiopulmonary resuscitation in dogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6697465" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Mechanisms by which epinephrine augments cerebral and myocardial perfusion during cardiopulmonary resuscitation in dogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7214942" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Mechanism of action of epinephrine in resuscitation from asphyxial arrest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32030529" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31926260" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Epinephrine in children receiving cardiopulmonary resuscitation for bradycardia with poor perfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31006260" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pulselessness After Initiation of Cardiopulmonary Resuscitation for Bradycardia in Hospitalized Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20956433" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pediatric basic and advanced life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22453726" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Primary cardiac arrest following sport or exertion in children presenting to an emergency department: chest compressions and early defibrillation can save lives, but is intravenous epinephrine always appropriate?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10890626" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Endotracheal versus intravenous epinephrine and atropine in out-of-hospital "primary" and postcountershock asystole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12009218" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Endotracheal drug administration during out-of-hospital resuscitation: where are the survivors?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26305650" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Time to Epinephrine and Survival After Pediatric In-Hospital Cardiac Arrest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30917838" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Time to epinephrine treatment is associated with the risk of mortality in children who achieve sustained ROSC after traumatic out-of-hospital cardiac arrest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31245334" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Early Epinephrine Improves the Stabilization of Initial Post-resuscitation Hemodynamics in Children With Non-shockable Out-of-Hospital Cardiac Arrest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29036580" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Time to epinephrine and survival after paediatric out-of-hospital cardiac arrest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29511001" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Time to Epinephrine Administration and Survival From Nonshockable Out-of-Hospital Cardiac Arrest Among Children and Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29317348" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Paediatric in-hospital cardiac arrest: Factors associated with survival and neurobehavioural outcome one year later.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28552658" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Epinephrine dosing interval and survival outcomes during pediatric in-hospital cardiac arrest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28552658" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Epinephrine dosing interval and survival outcomes during pediatric in-hospital cardiac arrest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34265230" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The Effect of Epinephrine Dosing Intervals on Outcomes from Pediatric In-Hospital Cardiac Arrest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31948649" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pre-Hospital Administration of Epinephrine in Pediatric Patients With Out-of-Hospital Cardiac Arrest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15102998" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A comparison of high-dose and standard-dose epinephrine in children with cardiac arrest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7761219" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : High-dose epinephrine in pediatric out-of-hospital cardiopulmonary arrest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9041296" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : High-dose epinephrine is not superior to standard-dose epinephrine in pediatric in-hospital cardiopulmonary arrest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8434845" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pediatric resuscitation pharmacology. Members of the Medications in Pediatric Resuscitation Panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1404773" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Guidelines for cardiopulmonary resuscitation and emergency cardiac care. Emergency Cardiac Care Committee and Subcommittees, American Heart Association. Part VII. Neonatal resuscitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Management of cardiac arrest</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4599470" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cardiovascular injury induced by sympathetic catecholamines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7956410" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The effect of the total cumulative epinephrine dose administered during human CPR on hemodynamic, oxygen transport, and utilization variables in the postresuscitation period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1404772" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Guidelines for cardiopulmonary resuscitation and emergency cardiac care. Emergency Cardiac Care Committee and Subcommittees, American Heart Association. Part VI. Pediatric advanced life support.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18339207" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Vasopressin and epinephrine in the treatment of cardiac arrest: an experimental study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Vasopressin and epinephrine versus epinephrine in management of patients with cardiac arrest: a meta-analysis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33612485" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Epinephrine Plus Vasopressin vs Epinephrine Plus Placebo in Pediatric Intensive Care Unit Cardiopulmonary Resuscitation: A Randomized Double Blind Controlled Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19188873" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Vasopressin for in-hospital pediatric cardiac arrest: results from the American Heart Association National Registry of Cardiopulmonary Resuscitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27974431" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : BET 2: Ice water immersion, other vagal manoeuvres or adenosine for SVT in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21946177" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Paediatric arrhythmias in the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24849273" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Use of adenosine in the treatment of supraventricular tachycardia in a pediatric emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25933212" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Treatment of supraventricular tachycardia in infants: Analysis of a large multicenter database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27912926" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Acute Management of Refractory and Unstable Pediatric Supraventricular Tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32327076" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Intravenous Sotalol in the Young: Safe and Effective Treatment With Standardized Protocols.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26314489" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Postural modification to the standard Valsalva manoeuvre for emergency treatment of supraventricular tachycardias (REVERT): a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29169907" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Upside-down position for the out of hospital management of children with supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20194798" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Amiodarone versus procainamide for the acute treatment of recurrent supraventricular tachycardia in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10220076" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Primary cardiac arrhythmias in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22241922" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Question 3 Does a higher initial dose of adenosine improve cardioversion rates in supraventricular tachycardia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17125432" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Therapeutic levels of intravenous procainamide in neonates: a retrospective assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28861756" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Management of Supraventricular Tachycardia in Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31871244" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Drugs Used to Treat Pediatric Emergencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9391691" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Pharmacologic management of supraventricular tachycardias in children. Part 2: Atrial flutter, atrial fibrillation, and junctional and atrial ectopic tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9391691" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Pharmacologic management of supraventricular tachycardias in children. Part 2: Atrial flutter, atrial fibrillation, and junctional and atrial ectopic tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26473000" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Part 12: Pediatric Advanced Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30571263" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : 2018 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations Summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30571264" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : 2018 American Heart Association Focused Update on Pediatric Advanced Life Support: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19495851" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Amiodarone for pediatric resuscitation: a word of caution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8609351" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Pediatric use of intravenous amiodarone: efficacy and safety in critically ill patients from a multicenter protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24361455" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Outcomes associated with amiodarone and lidocaine in the treatment of in-hospital pediatric cardiac arrest with pulseless ventricular tachycardia or ventricular fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31954741" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Lidocaine versus amiodarone for pediatric in-hospital cardiac arrest: An observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16316969" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Intravenous amiodarone for incessant tachyarrhythmias in children: a randomized, double-blind, antiarrhythmic drug trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24051016" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Pharmacokinetics of intravenous amiodarone in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5554942" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Effects of atropine on the electrocardiogram in different age groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3894677" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Experimental catecholamine-induced myocardial necrosis. I. Morphology, quantification and regional distribution of acute contraction band lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7906108" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Comparison of transesophageal atrial pacing with anticholinergic drugs for the treatment of intraoperative bradycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10459592" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The efficacy of atropine in the treatment of hemodynamically unstable bradycardia and atrioventricular block: prehospital and emergency department considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3752579" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Bradycardia delays the onset of action of intravenous atropine in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1898143" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Bezold-Jarisch reflex in postoperative pediatric cardiac surgical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1984729" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Systemic atropine administration during cardiac arrest does not cause fixed and dilated pupils.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1984729" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Systemic atropine administration during cardiac arrest does not cause fixed and dilated pupils.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5471208" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Autonomic blockade and the resting heart rate in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21382950" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : The myth of a minimum dose for atropine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9565215" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Premedication for neonatal intubation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4604546" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Hyperkalemia, cardiac conduction, and the electrocardiogram: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8216512" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Effect of hypertonic sodium bicarbonate in the treatment of moderate-to-severe cyclic antidepressant overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25526019" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : In-hospital pediatric cardiac arrest in Honduras.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29704520" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Trends in the incidence and outcome of paediatric out-of-hospital cardiac arrest: A 17-year observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24774393" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : In-hospital pediatric cardiac arrest in Spain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31404636" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Functional outcomes among survivors of pediatric in-hospital cardiac arrest are associated with baseline neurologic and functional status, but not with diastolic blood pressure during CPR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25008138" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Cardiac arrest and resuscitation in the pediatric intensive care unit: a prospective multicenter multinational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33662526" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Sodium bicarbonate administration during in-hospital pediatric cardiac arrest: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35880872" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Sodium Bicarbonate Use During Pediatric Cardiopulmonary Resuscitation: A Secondary Analysis of the ICU-RESUScitation Project Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31888123" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Use of Sodium Bicarbonate During Pediatric Cardiac Admissions with Cardiac Arrest: Who Gets It and What Does It Do?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3088448" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Difference in acid-base state between venous and arterial blood during cardiopulmonary resuscitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1326975" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Acid base changes in arterial and central venous blood during cardiopulmonary resuscitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4812073" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Cardiac arrest in the critically ill. II. Hyperosmolal states following cardiac arrest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1736913" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Prehospital bicarbonate use in cardiac arrest: a 3-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2827931" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Sodium bicarbonate in the perinatal setting--revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9057791" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Pharmacology of pediatric resuscitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32802" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : The hypotensive response to rapid intravenous administration of hypertonic solutions in man and in the rabbit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18450859" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Calcium use during in-hospital pediatric cardiopulmonary resuscitation: a report from the National Registry of Cardiopulmonary Resuscitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22990036" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Calcium administration during cardiac arrest:  a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31232852" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Cardiopulmonary Resuscitation in the Pediatric Cardiac Catheterization Laboratory: A Report From the American Heart Association's Get With the Guidelines-Resuscitation Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28062881" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Characteristics and Risk Factors for Mortality in Paediatric In-Hospital Cardiac Events in Singapore: Retrospective Single Centre Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35894607" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Calcium Administration During Cardiopulmonary Resuscitation for In-Hospital Cardiac Arrest in Children With Heart Disease Is Associated With Worse Survival-A Report From the American Heart Association's Get With The Guidelines-Resuscitation (GWTG-R) Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2246705" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : A prospective, randomized, double-blind comparison of calcium chloride and calcium gluconate therapies for hypocalcemia in critically ill children.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
